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ABBREVIATIONS$
 
3D   three-dimensional 
ADAM   a disintegrin and metalloproteinase 
AIDS   acquired immunodeficiency syndrome 
AKT   protein kinase B 
ANG   angiopoietin 
AP   activator protein 1 
ATG3   autophagy related 3 
α-SMA   alpha smooth muscle actin 
BEC   blood endothelial cell 
BMP   bone morphogenetic protein 
CAF   cancer associated fibroblast 
CCL/R   CC chemokine ligand/receptor  
CDC   Cell division control protein 
CXCL/R  CXC chemokine ligand/receptor 
CD   cluster of differentiation 
CDK   cyclin-dependent kinase 
COUP-TFII  COUP transcription factor 2 
COX-2   prostaglandin-endoperoxide synthase 2 
CREB   cyclic AMP response element-binding protein 
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
DDR DNA damage response 
DED dead effector domain 
DLL4   delta like ligand 4 
DNA   deoxyribonucleic acid 
dsDNA   double stranded DNA 
EBV   Epstein-Barr virus 
EC   endothelial cell 
E-cadherin  epithelial cadherin 
ECM   extracellular matrix 
EMT   epithelial to mesenchymal transition 
EndMT   endothelial to mesenchymal transition 
ErbB2   receptor tyrosine-protein kinase ErbB2, also known as HER2 
ERK   extracellular signal-regulated kinase 
FACS   fluorescence-activated cell sorting 
FAP   fibroblast activating protein 
FGF   fibroblast growth factor 
FSP-1   fibroblast specific protein 1 
GFP   green fluorescent protein 
HAART   highly active antiretroviral therapy 
H2Kb   H-2 Class I Histocompatibility Antigen K-B 
HES1    hairy enhancer of split 1 
HEY1    hairy/enhancer-of-split related with YRPW motif protein 1 
HGF   hepatocyte growth factor 
HHV-8   human herpes virus 8 
HIF-1α   hypoxia inducible factor 1α 
HIV   human immunodeficiency virus 
HPV   human papillomavirus 
HUVEC   human umbilical endothelial cell 
ICAM-1   intercellular adhesion molecule 1 
IGF-1   Insulin-like growth factor 1 
IκB NF-κB light polypeptide gene enhancer in B-cells inhibitor 
IKK   IκB kinase 
IL   interleukin 
iPSC   induced pluripotent stem cells 
KIT   Mast/stem cell growth factor receptor (SCFR) 
K-LEC   KSHV infected lymphatic endothelial cell 
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KS   Kaposi’s sarcoma 
KSHV   Kaposi’s sarcoma herpesvirus 
LANA   latency associated nuclear antigen 
LC3   Microtubule-associated protein 1A/1B-light chain 3 
LEC   lymphatic endothelial cell 
LYVE-1   lymphatic vessel endothelial hyaluronan receptor 1 
MAPK   mitogen activated protein kinase 
miRNA   microRNA 
MMP   matrix metalloproteinase 
MOI   multiplicity of infection 
mRNA   messenger RNA 
MR1   mannose receptor 1 
MT-MMP  membrane type matrix metalloprotease 
mTOR   mammalian target of rapamycin 
NF1   neurofibromin 1 
NFAT   Nuclear factor of activated T-cells 
NF-κB   nuclear factor kappa-B 
NICD   Notch intracellular domain 
NOD/SCID  nonobese diabetic/severe combined immunodeficient 
NPM   nucleophosmin 
p21   cyclin-dependent kinase inhibitor 1 
p27   cyclin-dependent kinase inhibitor 1B 
p65   protein 65 
PAGE   polyacrylamide gel electrophoresis 
PAR-1    Proteinase-Activated Receptor 1 
PCR   polymerase chain reaction 
PDGF   platelet-derived growth factor 
PECAM-1  platelet-endothelial cell adhesion molecule 1 
PEL   primary effusion lymphoma 
PI3K   Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PTEN   Phosphatase and tensin homolog 
Prox-1   prospero homeobox 1 
RAS   ‘Rat sarcoma’ protein 
Rb   retinoblastoma protein 
RBP-Jk   Recombining binding protein suppressor of hairless 
RNA   ribonucleic acid 
shRNA   short hairpin RNA 
siRNA   short interfering RNA 
SMAD   Mothers against decapentaplegic homolog 
SOX18   SRY (sex determining region Y)-box 18 
STAT   signal transducers and activators of transcription 
T-ALL   T-cell acute lymphoblastic leukemia 
TIMP    tissue inhibitors of metalloproteinases 
TAM   tumor associated macrophage 
TGF-β   transforming growth factor-β 
TNF   tumor necrosis factor 
TP53   tumor protein 53 
TPA   12-O-tetradecanoyl phorbyl-13-acetate 
TSA   tyramide signal amplification 
UV   ultraviolet 
VCAM-1  vascular adhesion molecule 1 
v-cyclin   viral cyclin 
VE-cadherin  vascular endothelial cadherin 
VEGF   vascular endothelial growth factor 
vFLIP   viral FLICE-inhibitory protein 
vGPCR   viral G protein-coupled receptor   
ZEB1/2   zinc finger E-box binding homeobox 1/2 
ZO-1   Zonula occludens, tight junction protein 1
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ABSTRACT$
Human tumorigenesis is a process in which a normal cell needs to acquire multiple 
characteristics to become malignant and metastatic. In short, these so called cancer 
hallmarks include increased proliferation and cell survival, as well as the ability to invade 
into the surroundings, induce angiogenesis, and finally metastasize to distant sites. These 
traits are regulated in a variety of different ways. However, some embryonic signaling 
pathways, including the Notch pathway, are able to regulate many of these processes. 
Furthermore, it has been shown that these signaling pathways can be deregulated in 
cancer, and that their untimely activation can lead to malignancies. In this study, Kaposi’s 
sarcoma herpesvirus (KSHV) associated malignancies, namely Kaposi’s sarcoma (KS) 
and primary effusion lymphoma (PEL), as well as melanoma have been used as model 
cancers. In all these malignancies, the tumor cells show alterations in cell identity and 
lineage marker expression, i.e. signs of cellular de- or transdifferentiation. In addition, the 
Notch pathway has been shown to be overly active in all of them. Thus, this thesis has 
focused on how the pro-tumorigenic traits are affected by cell plasticity and 
reprogramming in these cancers, and how the signaling pathways leading to these 
phenotypes, most notably Notch, are in turn regulated. Firstly, the results show that in vivo 
expression of a KSHV oncogene, viral (v-)cyclin, leads to activation of Notch signaling 
through Notch3 upregulation as well as fine-tuning of the NF-κB pathway through Cdk6 
mediated phosphorylation. These changes in turn lead to defects in T-lymphocyte 
differentiation and immune functions, as well as to the development of T-cell lymphomas. 
Secondly, this work demonstrates that KSHV infection in primary lymphatic endothelial 
cells (LECs) in three dimensional (3D) cell culture model leads to activation of a 
morphogenic process, endothelial to mesenchymal transition (EndMT), and increased 
invasiveness through activation of the Notch pathway and matrix metalloproteinase MT1-
MMP. Lastly, the data show that the changes in cell plasticity contributing to tumorigenic 
traits are not confined to virally induced cancers. Melanoma cell interaction with LECs 
leads to activation of the Notch pathway and increased adhesive, invasive, and metastatic 
properties of the tumor cells. In conclusion, the results show that regulation of cell 
plasticity through the Notch pathway takes place in different types of cancers, and it can 
affect several steps of tumorigenesis. A thorough and comprehensive understanding of the 
processes discovered herein may help develop better and more efficient treatments for 
these largely fatal malignancies. 
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TIIVISTELMÄ 
Monien normaalin solun ominaisuuksien tulee muuttua, ennen kuin solu muuntuu 
syöpäsoluksi ja pystyy leviämään elimistössä. Solun täytyy muun muassa pystyä 
jakautumaan hallitsemattomasti, tunkeutumaan ympäristöönsä, erittämään veri- ja 
imusuonien kasvuun vaikuttavia tekijöitä sekä lopulta pystyä hyödyntämään veri- ja 
imusuonistoa levitäkseen ympäriä kehoa. Syöpäsolujen eri ominaisuuksia säätelevät 
tyypillisesti eri signalointireitit, mutta eräät sikiönkehityksen aikana aktiivisesti toimivat 
reitit, kuten Notch-signalointi, voivat vaikuttaa moniin syöpäsolun ominaisuuksiin. 
Tällaisten signalointireittien yliaktiivisuus onkin liitetty syövän syntyyn ja leviämiseen. 
Tässä tutkimuksessa on käytetty malleina Kaposin sarkoomaan liittyvän herpesviruksen 
(KSHV) aiheuttamia syöpiä, Kaposin sarkoomaa (KS) ja primaaria efuusiolymfoomaa 
(PEL), sekä melanoomaa. Näissä kaikissa syövissä on havaittavissa, että syöpäsolujen 
soluidentiteetti on heterogeeninen, ja että syöpäsolut pystyvät ohjelmoitumaan uudelleen 
kasvuolosuhteidensa mukaan. Näille syöville on yhteistä myös, että Notch-signalointireitti 
on aktivoitunut. Tutkimukseni aiheena oli solujen muovautuvuus- ja ohjelmoitumiskyvyn 
vaikutukset syövän syntyyn ja leviämiseen ja näiden prosessien säätely. Työni 
ensimmäisessä osassa osoitin, kuinka KSHV:n onkogeenin v-sykliinin ilmentyminen 
hiiressä johtaa Notch- ja NF-κB- signalointireittien aktivoitumiseen ja sitä kautta T-
solujen erilaistumisen ja toiminnan häiriöön sekä T-solulymfooman kehittymiseen. 
Seuraavaksi näytin, kuinka KSHV-infektio imusuonten seinämän soluissa johtaa Notch-
signaloinnin aktivoitumiseen ja solujen uudelleenohjelmoitumiseen mesenkyymisolujen 
kaltaisiksi, jolloin ne pystyvät tehokkaammin tunkeutumaan ympäristöönsä. Lopuksi 
osoitin, että edellä kuvatut mekanismit eivät ole aktiivisia ainoastaan syöpävirusten 
aiheuttamissa kasvaimissa, vaan että myös melanoomasolujen interaktio imusuonten 
solujen kanssa aktivoi Notch-signalointia ja johtaa syöpäsolujen lisääntyneeseen adheesio-, 
invaasio- ja metastasoimiskykyyn. Notch-signalointi ja syöpäsolujen muovautumis- ja 
uudelleenohjelmoitumiskyky säätelevät siis monentyyppisten syöpien kehittymistä ja 
leviämistä. Näiden prosessien perusteellinen tuntemus mahdollistaa parempien ja 
tehokkaampien hoitojen kehittämisen näitä huonoennusteisia syöpiä vastaan. 
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INTRODUCTION$
The human tumor viruses, human papillomavirus (HPV), hepatitis B and C viruses, Epstein 
Barr virus (EBV), Kaposi’s sarcoma herpesvirus (KSHV), human T-cell lymphothropic 
virus, and Merkel cell polyomavirus, are estimated to cause 15-20% of all cancers 
worldwide. During their evolution they have hijacked cellular genes to their own genome 
which to date share homology which their host. KSHV genome consists of more than 
hundred open reading frames, including homologs of cyclin D, Flice inhibitory protein 
(FLIP) and G-protein coupled receptor, and it has proven to be an important tool in cancer 
biology research in general. An examination of virus induced tumors, and comparison of 
them to the human systems has potential to provide insight into the mechanisms and 
functions of both.  
 
Human tumorigenesis is a cascade of consecutive or simultaneous events that lead to the 
formation of a malignant cancer cell that can gain the ability to spread in the body. This 
process usually takes decades, and thus it is not surprising that all cancer cells within the 
same tumor are not identical, but exhibit signs of cellular heterogeneity. Moreover, it has 
been shown that deregulation and untimely activation of differentiation processes can alter 
the fate of the cancer cell: for example, expression of oncogenic c-Myc can lead to both 
altered differentiation and initiation of the tumorigenic process, whereas epithelial to 
mesenchymal transition has been shown to be crucial for the invasive capacities of epithelial 
tumors. However, the interplay of differentiation and tumorigenesis and the different phases 
of the process have remained rather obscure in many tumor types. Tumor cells in KSHV 
associated malignancies, Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), 
show signs of widespread lineage marker expression, suggesting that deregulation of 
cellular differentiation pathways and cell plasticity could contribute to the tumorigenesis of 
these cancers. Malignant melanoma shares similar features with KS and PEL, including 
plastic nature of the tumor cells associated to Notch pathway activation. Thus, we 
hypothesized that similar mechanisms might be involved in controlling its progression as 
well.  
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REVIEW$OF$THE$LITERATURE$
1.$HUMAN$TUMORIGENESIS$
All mammals have developed similar molecular mechanisms to control cell growth, 
differentiation and death. If the balance between these processes is disturbed, the cells can 
start proliferating uncontrollably. This might eventually lead to formation of a malignant 
tumor, cancer. The transformation from a normal cell to a cancer cell is a multistep 
process occurring via various routes in different malignancies. However, the required 
features are similar in all cancers (reviewed in Figure 1A, and (Hanahan and Weinberg, 
2000)). Briefly, transformed cells are autonomous from growth signals and resist 
inhibitory growth signals by inactivating the growth suppressive pathways and by 
upregulating cell survival signaling. They acquire limitless replicative potential by 
regaining the expression of an enzyme that prolongs the telomeres. The cancer cells are 
able to evade programmed cell death, apoptosis, by deregulating the apoptotic signaling 
pathways. To grow beyond certain size limit, the tumors regulate their oxygen and nutrient 
supply by inducing angiogenesis. Finally, in order to spread further, the tumor cells can 
develop capabilities which allow tissue invasion and metastasis to distant organs (Hanahan 
and Weinberg, 2000). In recent years, it has also become increasingly clear that cancer 
cells cannot gain all these abilities by themselves, but the surrounding stromal cells and 
the extracellular matrix (ECM) function actively in the transformation process in 
collaboration with the tumor cells (Quail and Joyce, 2013). 
 
 
 Figure$1.$Cancer$hallmarks$(A)$and$cell$cycle$progression$(B). 
(modified from (A) (Hanahan and Weinberg, 2011) and (B) (Aguilar and Fajas, 2010)) 
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1.1 CELL$TRANSFORMATION$
!
1.1.1$Cell$cycle$and$proliferation$signals$
For a cell to proliferate, the cell needs go through a cell division process called cell cycle. 
The main phases of the cell cycle (summarized in Figure 1B and ref. (Malumbres and 
Barbacid, 2009)) are DNA replication (S) phase and segregation of the newly synthesized 
daughter chromosomes in mitosis (M phase). These phases are preceded by two gap 
phases (G1 and G2), in which the cell is preparing for the S and M phases. Fluctuating 
levels of proteins specific for their respective cell cycle phase, called cyclins, control the 
phases. The cyclins act together with specific kinases, cyclin dependent kinases (CDKs). 
In the G1 phase, the cyclin D – CDK4/6 complex is active, which leads to phosphorylation 
of the retinoblastoma protein (pRb), its release from the transcription factor E2F, and 
synthesis of the G1-S proteins. These include cyclin E, which is an S phase cyclin that 
interacts with CDK2. In the early G2 phase, CDK2 interacts with cyclin A2, which in turn 
activates CDK1 later in the G2 phase. As a result, the cell enters mitosis, which is driven 
by the cyclin B-CDK1 complex. The cell cycle is further controlled by cell cycle 
inhibitors, which function by binding to and preventing the function of the cyclin-CDK 
complexes. The inhibitors are divided into two classes depending on their substrates. The 
INK4 family inhibitors block the cyclin D-CDK4/6 complex, whereas the CIP/KIP family 
members p21, p27, and p57 mainly regulate the cyclin E-CDK2 complex. Genetic mouse 
studies have revealed that apart from some highly differentiated cells, the interphase 
CDKs (CDK2, 4, 6) and cyclins (cyclin Ds and E) are dispensable for executing the cell 
cycle during development (Santamaria et al., 2007). Thus, it seems that CDK1 is sufficient 
to drive the cell cycle in normal conditions in mammals, and that the other cyclins are 
needed for additional control of proliferation of a wide array of specialized cells 
(Malumbres and Barbacid, 2009).  
 
The cell cycle is usually tightly regulated by mitogenic and anti-mitogenic signals. Typical 
signaling leading to cell proliferation involves a cell-extrinsic growth signal, which is 
mediated by binding of a ligand to a cell surface tyrosine kinase receptor. This initiates a 
phosphorylation cascade of various intracellular downstream targets leading to gene 
expression via activated transcription factors and finally cell cycle progression. Normal 
cells cannot proliferate without extracellular signals, which can be secreted growth factors, 
extracellular matrix (ECM) components, or intercellular interaction molecules such as 
integrins (Hanahan and Weinberg, 2000). However, in cancer, the cell cycle machinery 
might be activated without appropriate upstream regulation, in a process called 
unscheduled proliferation (Malumbres and Barbacid, 2009). Autonomous activation of 
cell cycle progression can occur at all steps of the proliferation cascade, including the cell 
cycle itself. In mice, transgenic expression of cyclin D/E, as well as germline silencing of 
p21 or p27 coding genes, gives rise to a variety of cancers (Santamaria and Ortega, 2006). 
pRb again functions as a haploinsufficient tumor suppressor, and pRb+/- mice develop 
endocrine tumors (Malumbres and Barbacid, 2001). Active cyclin D1- CDK4 complexes 
have also been shown to be necessary for breast cancer development due to ErbB2 
oncogene expression (Landis et al., 2006, Yu et al., 2001, Yu et al., 2006), suggesting that 
CDK4/6 activity is needed in cancer cells in contrast to most normal cells. This is 
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supported by reports showing that D- or E-type cyclins are often upregulated in cancer, 
whereas cell cycle inhibitors and pRb genes are frequently silenced, both leading to hyper 
activation of CDK4/6 seen in multiple tumor types including lymphoma, sarcoma, and 
melanoma (Malumbres and Barbacid, 2009).  
 
1.1.2$Regulation$of$apoptosis$
The programmed cell death, apoptosis, is utilized by multicellular organisms to balance 
the cell number and dispose of unnecessary or damaged cells. The apoptotic machinery 
can be activated by extracellular stimuli such as tumor necrosis factor alpha (TNFα), or 
intracellular stress stimuli, including DNA damage and overly active proliferation signals 
(Adams and Cory, 2007). The stress stimuli activate pro-apoptotic BH3 domain containing 
proteins, which are balanced by the anti-apoptotic Bcl-2 like proteins. The pro-apoptotic 
Bcl-2 family members function more downstream of the apoptotic cascade to control the 
permeability of the mitochondrial membrane to release cytochrome C (Adams and Cory, 
2007). Extra- and intracellular signals converge at the activation of apoptosis effector 
proteases called caspases, which in turn cleave hundreds of cellular proteins and DNA 
(Adams, 2003). Finally, the apoptotic cascade leads to disruption of cellular membranes, 
destruction of the cell skeleton, extrusion of the cytosol, degradation of chromosomes, and 
fragmentation of nuclei, which are then engulfed by the neighboring cells as well as the 
phagocytic system. 
 
In normal cells, many of the intracellular signals leading to apoptosis, most notably DNA 
damage but also hypoxia and oncogene hyperexpression, are sensed by the activation of 
p53. p53 is a transcription factor which promotes apoptosis by inducing the expression of 
pro-apoptotic Bcl-2 family members Noxa and Puma. In addition to apoptosis, p53 
activation can counteract the cell proliferation of damaged cells by activating the cell 
cycle checkpoints and inducing senescence (Brady and Attardi, 2010).  As oncogene 
activation in a normal cell would lead to initiation of apoptosis, there is a selection 
pressure for mutations in these apoptosis regulators. The importance of p53 in preventing 
cancer is highlighted by clinical data showing that it is functionally inactive in 50% of 
cancers, making it the most often mutated tumor suppressor (Fridman and Lowe, 2003). 
Additionally, both the anti- and pro-apoptotic Bcl-2 family members can be dysregulated 
in cancer to inhibit apoptosis (Adams and Cory, 2007). 
 
 
1.2$TUMOR$PROGRESSION$
Ninety percent of cancer deaths are due to distant organ metastasis, making it the key 
event in tumor progression. The multistep process of metastasis is described as an 
invasion-metastasis cascade, consisting of initial local invasion, angio-
/lymphangiogenesis, intravasation into blood and lymphatic vessels, transit through the 
vascular systems, extravasation into distant sites, formation of small non-proliferating 
colonies called micrometastases, and finally growth of these colonies to form 
macrometastases (summarized in Figure 2). In recent years, the understanding has 
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increased substantially of the timing of metastasis, complexity of the dissemination routes, 
and the intricacy of the mechanisms behind the organ tropism and dictation of 
micrometastasis growth (Sleeman et al., 2011). 
 
$
Figure$2.$Invasion3metastasis$cascade.$
(modified from (Reymond et al., 2013))$
$
1.2.1$Local$invasion$$
When the tumor progresses from the pre-malignant stages to an invasive tumor, it needs 
the capability to invade into its surroundings. The key events in local invasion are changes 
in cell adhesion, activation of proteolysis, and increased motility, which can be achieved 
by inducing morphogenetic processes such as epithelial to mesenchymal transition (EMT, 
discussed more in chapter 2.1.2) (Hanahan and Weinberg, 2011). Tumor cells can migrate 
in two main ways, individually or collectively, and single-cell invasion can be further 
divided into amoeboid and mesenchymal invasion modes (Friedl and Alexander, 2011). 
Even though the invasion mode has been thought to be tumor type specific, it has lately 
been recognized that tumors can alternate between different migration patterns depending 
on their surroundings, i.e., the ECM composition and structural constraints or trails such 
as blood vessels (Haeger et al., 2014, Wolf et al., 2013). Active cell migration can be 
divided into five steps taking place in the individually migrating cell, or in the leading cell 
of the collectively invading mass (Friedl and Wolf, 2009). These steps include actin 
polymerization, adhering to the ECM via integrins, proteolysis mediated by 
metalloproteases such as matrix metalloproteinases (MMPs), contraction of the cellular 
cytoskeleton, and finally cell movement (Friedl and Wolf, 2009).  
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1.2.1.1$Matrix$metalloproteinases$(MMPs)$
Matrix degrading proteases such as MMPs are key effectors of tissue invasion by cleaving 
the ECM components including collagens, non-collagenous glycoproteins (e.g. laminins, 
fibronectin), and proteoglycans (e.g. perlecan, decorin, or CD44) (Sevenich and Joyce, 
2014). As the proteolytic cleavages by MMPs are irreversible events, it is not surprising 
that their gene expression, activity, and subcellular localization are strictly controlled 
(Kessenbrock et al., 2010). MMPs are activated from an inactive zymogen to an active 
enzyme by proteolytic removal of the pro-domain. Usually this is achieved by the activity 
of other proteases, such as plasmin, furin, or active MMP (Sternlicht and Werb, 2001). 
MMPs are either membrane bound (MT1-MMP-MT3-MMP) or secreted into the 
extracellular space (e.g. MMP1-MMP9) (Nagase et al., 2006). The active membrane 
bound enzymes localize to plasma membrane structures called invadopodia at high local 
concentrations (Murphy and Courtneidge, 2011), while secreted MMPs can act on the cell 
surface as well by binding to cell surface integrins and CD44 (Redondo-Munoz et al., 
2008). MMP activity is additionally controlled by endogenous inhibitors such as tissue 
inhibitors of metalloproteinases (TIMPs) (Deryugina and Quigley, 2006). The proteases, 
their substrates and inhibitors form highly interconnected proteolytic networks, making 
the regulation of MMP activity extremely complex (Fortelny et al., 2014).   
 
The expression of proteases is often upregulated in cancer and correlates to poor patient 
prognosis (Sevenich and Joyce, 2014). MMPs are mostly derived from the stromal cells in 
tumors (Egeblad and Werb, 2002), and they modify tumor progression in multiple ways. 
These include accelerated tumor growth, increased tissue remodeling, inflammation, tissue 
invasion, and metastasis (Kessenbrock et al., 2010). ECM remodeling leads to the 
formation of spaces for the invading cells, as well as to the generation of active ECM 
epitopes that promote cell adhesion and migration (Friedl and Alexander, 2011). In 
addition, MMPs can regulate the bioavailability of growth factors to tumor cells and 
endothelial cells (ECs) by cleaving the ECM and releasing the bound growth factors, thus 
inducing tumor cell proliferation and angiogenesis (Sevenich and Joyce, 2014). MMPs can 
also regulate the availability of cell surface molecules, including growth factor receptors 
(Overall and Blobel, 2007). MMPs have been shown to degrade cell adhesion molecules 
and intercellular junction proteins and, thus, further facilitate invasion. For example, 
MMP3 and MMP7 can cleave E-cadherin, mediate EMT, and reinforce the invasive 
capacity of epithelial tumor cells (Noe et al., 2001). In addition, MMPs are involved in 
intra- and extravasation in multiple ways. MMP17 has been shown to promote pericyte 
detachment from blood vessels, leading to vascular leakiness and tumor cell invasion to 
the vessels (Chabottaux et al., 2009). MMP1, on the other hand, has been shown to cleave 
Proteinase-Activated Receptor 1 (PAR-1) on ECs, which leads to loosened cell-cell 
contacts, thus increasing transendothelial migration of cancer cells (Juncker-Jensen et al., 
2013).   
 
 
 
  
!
REVIEW(OF(THE(LITERATURE(
!
! !
18 
1.2.2$Tumor$angiogenesis$
Vasculature is divided into two distinct but connected systems, the blood and the 
lymphatic vasculature. The function of the blood vasculature system is to provide oxygen 
and nutrients to cells, whereas the lymphatic vessel system functions as a gatekeeper of 
fluid homeostasis. In tumors, cancer cells use these systems additionally as highways for 
spreading, and therefore promote the formation of new vessels. Furthermore, increasing 
evidence shows that ECs actively interact with their surroundings and regulate tissue 
homeostasis for example by producing cytokines (discussed more in chapter 2.2.2). 
 
1.2.2.1$Angiogenesis$
Normally, the formation of new blood vessels is restricted to embryogenesis and some 
transient processes such as wound healing, and most of the vasculature in adults is in 
quiescent state. However, to enable tumor growth beyond 1 mm diameter, the tumors need 
to gain ability to grow new blood vessels from the pre-existing ones, i.e., activate 
sprouting angiogenesis in a process called ‘angiogenic switch’ (Hanahan and Folkman, 
1996). The angiogenic switch occurs quite early in the tumorigenic process, as already 
non-invasive premalignant lesions show signs of it both in animal models and in human 
tissue (Raica et al., 2009). After initial activation of angiogenesis, different tumors show 
diverse patterns of neovasculature, nonetheless, the tumor vasculature is characteristically 
aberrant. The vessels exhibit extensive, serpentine sprouting and distorted, enlarged 
morphology. The blood flow is erratic, leading to insufficient supply of nutrients and 
removal of metabolites. In addition, the vessels are hyperpermeable, which leads to micro-
hemorrhaging and accumulation of fibrin into the tumor, which assists tumor cell 
migration and subsequent stroma formation (Nagy et al., 2010).  
 
The angiogenic switch is controlled by tilting the balance of pro-angiogenic factors and 
angiogenesis inhibitors secreted by the tumor cells or the tumor microenvironment 
towards induction of angiogenesis (Baeriswyl and Christofori, 2009). In tumors, the pro-
angiogenic factors are generally expressed at high levels and inhibitors at low levels 
compared to corresponding normal tissues. The most profound pro-angiogenic factor is 
the vascular endothelial growth factor (VEGF-A), acting in collaboration with a plethora 
of other factors such as fibroblast growth factors (FGFs), platelet-derived growth factors 
(PDGFs), and Notch (Carmeliet and Jain, 2011). In tumor cells, there are several ways 
how VEGF-A expression is induced. These include cellular stress factors such as hypoxia 
inducible factor α (HIF-1α), as well as oncogenes and inactivated tumor suppressors 
(Baeriswyl and Christofori, 2009). VEGF-A signals through cell surface tyrosine kinase 
receptors (VEGFR-1-3) on endothelial cells. Mostly it mediates its angiogenic functions 
through VEGFR-2 (Koch et al., 2011). Activation of VEGFR-2 is initiated by 
dimerization to homo- or heterodimers with other VEGFRs, and auto- or 
transphosphorylation of specific tyrosine residues (Koch et al., 2011). This leads to 
phosphorylation and activation of downstream effectors along the PKC/ERK pathway, and 
finally to proliferation of the endothelial cells. Other biological responses to VEGFR-2 
activation include migration, survival, and vascular permeability (Koch et al., 2011).  
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1.2.2.2$Lymphangiogenesis$
In addition to the blood vascular system, the lymphatic system contributes to normal tissue 
homeostasis and cancer pathogenesis. In normal tissues, it has important functions in 
controlling interstitial fluid homeostasis, lipid absorption, and immune responses (Zheng 
et al., 2014a). Lymphatic capillaries have several characteristics which distinguish them 
from blood capillaries: they lack pericytes, have discontinuous basement membranes and 
button-like (cell-cell) intercellular junctions made of vascular endothelial cadherin (VE-
cadherin) and other junction proteins (Alitalo, 2011).  The capillaries drain into 
precollector vessels, sparsely covered by smooth muscle cells. The lymph then moves to 
the collecting lymphatic vessels, which are surrounded by smooth muscle cells and have 
basement membrane and continuous interendothelial cell junctions (Alitalo, 2011). 
Specific markers such as Prox-1, VEGFR-3, podoplanin and LYVE-1 distinguish the 
lymphatic ECs (LECs) from their vascular counterparts, blood ECs (BECs) (Albrecht and 
Christofori, 2011). Many of the markers have important functions in the embryonic 
differentiation of LECs from veins, as well as maintaining LEC identity. In embryonic 
veins, transcription factors SOX18 and COUP-TFII co-operate to activate Prox-1. 
Transcription factor Prox-1 is considered to be the master regulator of LEC fate (Johnson 
et al., 2008), and it controls the expression of other genes associated with LEC 
characteristics (Petrova et al., 2002). These genes include VEGFR-3, which is needed in 
sprouting angiogenesis towards its ligand VEGF-C. Final separation of veins and the 
lymphatic system in the embryo takes place with the aid of podoplanin, which triggers 
platelet aggregation and thus blocks the blood flow (Zheng et al., 2014a).  
 
In adults, the main route to create new lymphatic vessels is sprouting from the pre-existing 
ones, in a process called lymphangiogenesis. Several factors influence this process, but 
VEGF-C/VEGFR-3 is the most important pathway. Binding of VEGF-C to VEGFR-3 
leads to its dimerization and autophosphorylation. This leads to activation of downstream 
serine kinases AKT and ERK, and finally proliferation, migration and survival of LECs 
(Makinen et al., 2001). In addition, the VEGF-C stimulated angiogenesis is aided by many 
other secreted factors such as angiopoietin 2 (ANG-2), FGFs, and VEGF-VEGFR-2 axis. 
Lymphangiogenesis is additionally influenced by cell-cell contact mediated signaling via 
the Notch and ephrin pathways (Zheng et al., 2014a). Notch inhibition has been shown to 
synergize with VEGF to induce lymphangiogenesis in adult mice and in 3D cell models 
(Zheng et al., 2011), whereas EphrinB2 facilitates VEGF3 signaling (Wang et al., 2010). 
At the same time, lymphangiogenesis is balanced by endogenous inhibitors, including 
transforming growth factor β (TGF-β) and bone morphogenetic protein 2 (BMP-2) (Zheng 
et al., 2014b).  
 
Similar to tumor blood vasculature, the tumor associated lymphatic vessels differ from 
their normal counterparts. High interstitial pressure inside the tumor leads to collapsed, 
poorly functional vessels, whereas in the periphery of the tumor the vessels are functional 
and thought to contribute to metastasis. In transcriptional profiling studies the tumor 
lymphatic vessels resemble activated, growing lymphatic vessels, and express markers of 
active lymphangiogenesis (Albrecht and Christofori, 2011). Additionally, LEC-LEC and 
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LEC-matrix interactions are altered in the tumors (Clasper 2008, Milteva 2010). The 
increased numbers of lymphatic vessels in the tumors and sentinel lymph nodes are mainly 
achieved by sprouting angiogenesis (Albrecht and Christofori, 2011). Lymphangiogenesis 
is initiated by tumor cells or stromal cells, especially tumor associated macrophages 
(TAMs), which express lymphangiogenic factors like VEGF-C and ANG-2 (Ji, 2012). In 
addition, other growth factors, including VEGF-A, FGF, PDGF-B, HGF, IGF-1, are 
overexpressed in the tumors and can induce lymphangiogenesis by more indirect 
mechanisms, for example by recruiting inflammatory cells (Zheng et al., 2014a). 
Incorporation of bone marrow derived progenitor cells have been described as another 
mechanism participating in the formation of new lymphatic vessels, albeit at low numbers 
(Patenaude et al., 2010).   
 
1.2.3$Hematogenic$spread$and$colonization$to$distant$organs$
In order to metastasize, cancer cells need to reach distant sites through one of the vascular 
systems. Spread via blood vasculature requires intravasation into the vessels, survival 
inside the vessels, and finally extravasation. As large numbers of cancer cells are shed into 
the circulation every day, but not all patients develop metastasis, it seems that 
intravasation is necessary but not sufficient for metastasis (Sleeman et al., 2011). In 
extravasation, cancer cells actively transmigrate through the capillary walls, while the 
endothelial junction proteins are downregulated and the ECs retract (Garcia-Roman and 
Zentella-Dehesa, 2013). For successful extravasation, a contribution from platelets, 
leukocytes, and macrophages is required (Gay and Felding-Habermann, 2011).  
 
Many of the extravasated cells initially enter dormancy, but they can be activated to grow 
even decades after removal of the primary tumor. Analysis of tumor growth rates and 
single cell genomics of dormant tumor cells indeed suggest that tumor cell spread to 
distant organs is an early event (Husemann et al., 2008, Klein and Holzel, 2006), and the 
disseminated cells probably remain dormant before they gain ability to grow metastases 
(Klein, 2009).  The signals that lead to the activation of dormant tumor cells are not fully 
understood, but modifications of the microenvironment to form a metastatic niche seem to 
play an important role. The central elements of the metastatic niche include perivascular 
location, modifications of the ECM, recruitment of bone marrow derived cells, hypoxia, 
and the expression of certain signaling molecules (Sleeman, 2012).  
 
1.2.4$Contribution$of$the$lymphatic$system$to$metastasis$
Lymphatic vessels can act as conduits for the tumor cells to metastasize. The high 
interstitial pressure in tumors and the high fluid flow facilitate invasion of tumor cells into 
the lymphatic vessels. The intrinsic properties of the lymphatic vessels, discontinuous 
contacts and smooth muscle coverage, and lack of basement membrane, make them fairly 
easily accessible to tumor cells. In addition, there is lower mechanical stress inside the 
lymphatic vessels than inside blood vessels. In human tumors, it has been observed that 
the lymphatic vessels can also host tumor cells themselves. In transit metastasis between 
the primary tumor and the sentinel lymph node is a likely example of this. Twenty percent 
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of melanoma patients who have undergone full primary tumor resection show signs of 
such lymphatic contribution (Alitalo, 2011). The status of lymph node metastasis 
correlates with prognosis, even though the lymph node metastases themselves usually are 
not fatal (Morton et al., 2006). In breast cancer and melanoma, which arise in tissues with 
abundant lymphatic vasculature, this is particularly clear. In these tumor types, draining or 
“sentinel” lymph node biopsy is used as part of clinical practice to facilitate prognosis and 
to establish treatment regime. However, the probability of distant organ metastasis and 
overall survival is not affected by the removal of sentinel or other draining lymph nodes 
(Sleeman et al., 2011). This suggests that lymph node metastasis does not serve as an 
additional source of disseminating tumor cells. To explain this paradigm, Klein and Holzel 
have suggested a parallel dissemination model, in which the tumors produce factors that 
can simultaneously activate lymphangiogenesis and act systemically to promote distant 
metastasis (Sleeman et al., 2009, Sleeman and Thiele, 2009, Klein and Holzel, 2006).  
 
Mechanistically, tumor cells have been shown to interact with the lymphatic system in 
multiple ways: tumor cells can activate lymphangiogenesis, co-opt pre-existing lymphatic 
vessels, invade into them, and use factors secreted by the LECs as chemotactic clues 
(Sleeman and Thiele, 2009, Alitalo and Detmar, 2012). In some human cancer types, there 
are reports of a correlation between the density of lymphatic vessels, extent of lymphatic 
vessel invasion, and lymphangiogenic growth factor levels to lymph node and distant 
metastasis, and poor prognosis (Dadras et al., 2005, Dadras et al., 2003). This suggests 
that lymphangiogenic factors play an important role in metastasis.  Indeed, data from 
animal models have shown that inhibition of VEGF-C/D-VEGFR3, COX-2, and PDGF-B 
activity reduces tumor-induced lymphangiogenesis, while the forced expression of VEGF-
C/D induces lymph node and distant organ metastasis (He et al., 2002, Karpanen et al., 
2001, Mandriota et al., 2001, Skobe et al., 2001, Stacker et al., 2001, Yanai et al., 2001). 
Tumor entry and metastasis can also be facilitated by the proliferation of LECs in the 
collective lymphatic vessels and lymph nodes by VEGF-A/C mediated mechanisms 
(Hirakawa et al., 2007, Hirakawa et al., 2005). Nevertheless, lymph node metastasis is not 
always associated with increased lymphangiogenesis. Especially in tissues with high 
lymphatic vessel content, tumor cells can co-opt pre-existing lymphatic vessels and 
metastasize without additional lymphangiogenesis (Sleeman et al., 2009). To invade into 
lymphatic vessels, tumor cells can secrete factors such as lipoxygenase, which 
downregulate LEC cell-cell contact molecules (Kerjaschki et al., 2011). Tumor lymphatic 
cells express specific adhesion molecules, including macrophage mannose receptor 1 
(MR1) and CLEVER-1, which can be utilized by the tumor cells to attach to the lymphatic 
vessels and facilitate invasion (Irjala et al., 2003, Karikoski et al., 2014). Tumor cells can 
also hijack the immune cell attraction, adhesion, and homing mechanisms to the lymph 
nodes. This has been shown to occur through the chemokines such as CCL21 and 
CXCL12, secreted by the LECs, which attract tumor cells toward lymphatic vessels and 
support tumor growth (Aebischer et al., 2014, Hirakawa et al., 2009, Karaman and 
Detmar, 2014). Tumors can induce immunosuppression in the tumor draining lymph 
nodes by reducing the number and weakening the function of immune cells recognizing 
the tumor, thus further promoting tumorigenesis and impairing patient survival (Madsen, 
Sahai 2010).  
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2.$CELLULAR$REPROGRAMMING$AND$TUMOR3STROMA$INTERACTIONS$
 
It has become increasingly evident that tumors consist not only of a mass of mutated 
cancer cells but also of a vivid stromal component which interacts with the tumor cells and 
actively participates in the malignant process. Tumor stroma consists of basically the same 
elements as any other tissue, namely ECM, supporting cells such as fibroblasts, blood and 
lymphatic vessels, pericytes, and immune system components. However, the origin of the 
cells might differ from their normal counterparts, and their function is altered due to the 
active interaction with tumor cells (Quail and Joyce, 2013). The ECM can also promote 
tumorigenesis as it functions as a reservoir of cytokines and growth factors, the 
bioavailability of which is regulated by matrix degrading enzymes (Sevenich and Joyce, 
2014). Moreover, tumor cells can mimic the properties of stromal cells and use these 
gained traits for their advantage in the malignant progression. Examples of such processes 
include transdifferentiation, in which a cell fate is converted from one differentiated cell 
type to another mature cell type (Campos-Sanchez and Cobaleda, 2014). The most well-
characterized example of this is epithelial to mesenchymal transition (EMT), in which 
epithelial tumor cells adapt characteristics of mesenchymal cells to help their invasion into 
the surrounding tissues (Thiery, 2002). Tumor cells can additionally mimic other stromal 
components, for example, ECs in a process called vascular mimicry. This is a source of 
functional blood vessels in the tumor, leading to better survival of the tumor cells (Seftor 
et al., 2012). Furthermore, tumor cells have been described to be able to dedifferentiate, 
i.e., revert the normal differentiation and give rise to progenitors of the same phylogenic 
tree. These cells serve as reservoirs to produce more differentiated cancer cells, and are 
sometimes called cancer stem cells (Campos-Sanchez and Cobaleda, 2014). The tumor 
cells are not solely capable of differentiating into the stromal cells, but the stromal cells 
can also transdifferentiate into other stromal cell types. ECs can serve as sources for 
cancer associated fibroblasts through a process called endothelial to mesenchymal 
transition (EndMT) (Potenta et al., 2008), and macrophages have been shown to be able to 
transdifferentiate into LEC progenitors, and possibly contribute to the tumor 
lymphangiogenesis (Patenaude et al., 2010).  
 
2.1$CELLULAR$REPROGRAMMING$IN$CANCER$
2.1.1$Oncogenes$induce$cell$fate$changes$
The terminal differentiation of cells restricts cell proliferation by instructing the cells to 
enter irreversibly into a post-mitotic state. In cancer, oncogenes can hinder the 
differentiation programs, i.e., reprogram the cell, to favor cell proliferation. The best-
characterized example is the c-Myc oncogene, which is overexpressed in many cancers 
leading to a proliferative phenotype. Conditional mouse models have shown that if c-Myc 
expression is shut down in tumors, the cancer cells can enter a terminal differentiation 
program, senescence, or apoptosis (Gabay et al., 2014). This suggests that in some cancers 
constitutive oncogene expression is needed to prevent the cells from differentiating and 
going into a non-proliferative state. Furthermore, cancer can be seen as a set of oncogenic 
alterations leading to reprogramming of the normal cellular identity to form a new 
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pathogenic lineage (Campos-Sanchez and Cobaleda, 2014, Goding et al., 2014). Studies 
on the reprogramming of cells to pluripotency have highlighted the similarities between 
cancer progression and generation of induced pluripotent stem cells (iPSC). In both, the 
cells acquire unlimited proliferation and self-renewing abilities (Semi et al., 2013). 
Additionally, the original four reprogramming transcription factors, c-Myc, Oct4, Klf4, 
and Sox2, needed to reprogram fibroblasts into iPSCs (Takahashi and Yamanaka, 2006), 
were already earlier described to have oncogenic capacities. The establishment of these 
factors in the induction of pluripotency further emphasized that despite the complex 
interplay between transcription factors and the epigenetic landscape in maintaining the 
cellular identity, a limited number of cellular genes can fully bypass these mechanisms. 
This suggests that in cancer as well the function of only a few oncogenes can be sufficient 
to change the fate of the cell, but in a cell type dependent manner. Other studies have 
indeed shown that an alteration in the expression of a single transcription factor might 
even be enough for cell fate changes such as dedifferentiation and transdifferentiation. For 
example, elimination of Pax5 expression, which is the driver of B-cell identity, leads to 
the dedifferentiation of B-cells to hematopoietic progenitors and aggressive progenitor cell 
lymphomas (Cobaleda et al., 2007). 
 
2.1.2$Mesenchymal$transitions$
2.1.2.1$Epithelial$to$mesenchymal$transition$(EMT)$$
EMT is characterized as replacement of the quiescent epithelial phenotype by an invasive 
and migratory mesenchymal phenotype (summarized in Figure 3). In normal development, 
repetitive rounds of EMT and the opposite process, mesenchymal to epithelial transition 
(MET), are necessary for completing the gastrulation and primitive streak formation. In 
addition, EMT is needed for the cells to migrate to different sites in the body during 
embryogenesis (Nieto, 2013). Tumor cells have adapted to use these morphogenic 
processes to spread.  EMT can mostly be seen at the borders of the tumor, and it gives rise 
to invasive and migratory cells that intrude into the surrounding stroma. The reversibility 
of the process is also used by the tumor cells: EMT allows them to leave the primary 
tumor site, whereas MET is used by them to colonize at the metastatic sites (Thiery, 
2002).  EMT is defined by the loss of expression of the cell-cell contact markers, such as 
E-cadherin and tight junction proteins, and the gain of expression of mesenchymal 
markers, including vimentin, fibronectin, fibroblast specific protein (FSP-1), alpha smooth 
muscle actin (α-SMA), and N-cadherin (Kalluri and Weinberg, 2009). As the cell 
cytoskeleton is rearranged as well, the cell shape changes to spindle like, resembling 
fibroblasts. The initiation of these processes is controlled by specific growth factors and 
cytokines, hypoxia through HIF-1α, as well as contacts with the ECM (Gonzalez and 
Medici, 2014). These signals work in cell and tissue type specific manner, and lead to 
activation of signaling pathways such as TGF-β, BMP, FGF, PDGF, and Notch (Espinoza 
and Miele, 2013, Heldin et al., 2012, Katoh and Katoh, 2009, McCormack and O'Dea, 
2013). The initiated intracellular kinase cascade leads to activation of specific 
transcription factors, which mediate the EMT process. The transcription factors include 
Snail, Slug, Twist, and ZEB1/2, which have been shown to act on the E-cadherin gene 
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(CDH1) promoter and inactivate it (Peinado et al., 2004, Yang et al., 2004). In addition, 
the same factors can repress the epithelial adherent junction proteins, leading to 
dissociation of the cell-cell contacts (Eger et al., 2005, Vandewalle et al., 2005). ZEB1/2 
has also been shown to increase the expression of MMPs and subsequently the invasive 
and migratory capacity of the cells (Miyoshi et al., 2004). 
 
2.1.2.2$Endothelial$to$mesenchymal$transition$(EndMT)$
ECs exhibit diversity in their gene expression depending not only on their localization in 
the vascular tree but also on the tissue environment (Chi et al., 2003). An example of EC 
plasticity beyond the endothelial fate is EndMT, where the endothelial cell features are 
replaced by the mesenchymal phenotype (see Figure 3 and (Armstrong and Bischoff, 
2004)). EndMT is a reprogramming program sharing characteristics with EMT (Saito, 
2013). Similar to EMT, EndMT occurs in the normal development. EndMT is best studied 
in the developing heart, where it takes place in the formation of the valves and septa from 
the endoderm (Garside et al., 2013). EndMT can additionally function in pathological 
conditions, including cancer and cardiac fibrosis (Zeisberg et al., 2007a, Zeisberg et al., 
2007b, Potenta et al., 2008), as well as contribute to the formation of the mesenchymal 
stem cell phenotype (Medici and Kalluri, 2012, Medici et al., 2010), which can further 
give rise to pathological ossification (Medici and Olsen, 2012). In cancer, in vivo studies 
have suggested that EndMT can serve as a significant source of cancer associated 
fibroblasts (CAFs), which have an established role in tumor progression (Zeisberg et al., 
2007a). The characteristics of EndMT include losing the EC markers (PECAM, Tie1, 
Tie2, VEGFR), loosening of the endothelial junctions (VE-cadherin), gaining markers of 
the mesenchymal cells (FSP-1, α-SMA, fibronectin, vitronectin, collagen types I and II), 
and increasing the invasive and migratory properties (Potenta et al., 2008). Most of the 
studies on EndMT regulation have concentrated on developmental EndMT, and shown 
that it can be induced by the coordinated function of TGF-β, Notch, and BMP pathways 
(Garside et al., 2013). For example, the conditional mouse knockouts of TGF-β2, BMP-2 
and BMP-4 are defective for EndMT induced phenotypes (Azhar et al., 2009, Ma et al., 
2005, McCulley et al., 2008). Additional pathways, including VEGF, NFAT, Wnt, ErbB 
and NF1/Ras, have also been implicated to be involved in EndMT associated with heart 
development (Armstrong and Bischoff, 2004). Downstream effects, such as the 
downregulation of VE-cadherin expression, seem to be mediated by the Snail family of 
transcriptional repressors (Medici et al., 2011). However, their expression is not sufficient 
to cause EndMT: It has been recently shown that Slug expression in ECs can lead only to 
partial EndMT. This further leads to MT1-MMP expression and angiogenic sprouting 
(Welch-Reardon et al., 2014a, Welch-Reardon et al., 2014b). 
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$
$
Figure$3.$EMT/EndMT.$
Morphogenic processes EMT and EndMT result in loss of epithelial/endothelial markers 
(indicated in the two white boxes on the left) and gain of mesenchymal markers (listed in 
the black box on the right). Finally, this leads to increased cancer cell invasion and can 
give rise to CAFs. TGF-β, Notch, BMP, Wnt, and NF-κB signaling have been shown to 
induce EMT/EndMT through transcription factors Snail, Slug, and ZEB1/2 (modified 
from (Miyazono, 2009)). 
 
2.1.3$Selected$cellular$pathways$deregulating$differentiation$in$cancer$
2.1.3.1$Notch$signaling$pathway$
The Notch pathway has been implicated to be important in regulating proliferation, 
differentiation and survival/apoptosis both in development and pathological conditions 
such as cancer (Guruharsha et al., 2012). Furthermore, it has been shown to be involved in 
the maintenance of the stem cell properties, angiogenesis, and morphogenic processes 
such as EMT and EndMT (Dzierzak and Speck, 2008, Kofler et al., 2011, Espinoza and 
Miele, 2013). In mammals, there are four Notch receptors (Notch1-4), which bind ligands 
belonging to the delta like (Dll1 and Dll3-4) or Jagged (Jag1-2) families. As both the 
receptors and ligands are membrane bound, the pathway activation needs cell-cell contact 
between ligand expressing and receptor expressing cells. The ligand binding results in a 
conformational change of the receptor, allowing disintegrin and metalloproteinase 10 
and/or 17 (ADAM10 and/or ADAM17) to cleave the extracellular part of the receptor. 
This subsequently enables γ-secretase enzyme to cleave the receptor from the intracellular 
side resulting in formation of Notch intracellular domain (NICD), which can then 
translocate to the nucleus. There it binds transcription factor RBP-Jκ, which allows RBP-
Jκ dissociation from its repressor complex, and association with transcription activators 
such as MAML and p300 (reviewed in (Lobry et al., 2014)). The formed complex acts as 
transcriptional regulator of the Notch pathway targets, including the most well 
characterized hairy enhancer of split (Hes) family of transcription repressors, the Notch-
related ankyrin repeat protein (Nrarp), c-Myc, and cyclin D1 and D3 (Borggrefe and 
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Oswald, 2009). In addition, the Notch pathway has been shown to regulate a large number 
of additional genes, many of them cell-type specific (Borggrefe and Oswald, 2009, 
Hamidi et al., 2011). The Notch pathway activation is summarized in Figure 4, which 
additionally shows the KSHV regulation of Notch described in more detail in chapter 3.1 
and ref. (Cheng et al., 2012). 
 
 
Figure$4.$Notch$pathway$activation,$and$how$it$is$steered$by$KSHV.$
Summary of Notch pathway activation is show in bold, while the KSHV regulators of the 
Notch pathway are with red background. CoR= transcription co-repressors; CoA= 
transcription co-activators; modified from (Cheng et al., 2012). 
 
 
$ 2.1.3.1.1$Notch$signaling$in$differentiation$and$tumorigenesis 
The role of Notch pathway has been studied most profoundly in the hematopoietic system, 
where Notch signaling has been shown to be an essential regulator of the proliferation, 
self-renewal, and differentiation of the hematopoietic stem and progenitor cells. Notch 
pathway activation is sufficient for the cell fate determination of T-cells over B-cells, as 
DLL4 activates T-cell differentiation processes of the primary human CD34+ cells (Lefort 
et al., 2006). In addition, Notch-RBP-Jκ regulates the differentiation of marginal zone B-
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cells as well as αβ−T-cells (Tanigaki et al., 2002, Tanigaki et al., 2004). Moreover, the 
imbalance in the Notch signaling can lead to alteration in these processes causing 
transformation (Kushwah et al., 2014). 
 
Regulation of cell differentiation by Notch is compatible with the diverse role of Notch in 
different malignancies. It has been found to be oncogenic in many of the cell types where 
its activity is needed for differentiation. The most profound example of this is the role of 
activated Notch in T-cell leukemo-/lymphomagenesis (Aifantis et al., 2008). In humans, 
activating mutations in NOTCH1 have been described in 56% of human T-cell acute 
lymphoblastic leukemia (T-ALL), making NOTCH1 the most frequently mutated gene in 
T-ALL (Weng et al., 2004). Most probably, these mutations lead to MYC oncogene 
activation and inactivation of the tumor suppressors p16 and p14 in hematopoietic 
progenitors, which leads to differentiation towards T-cell development (Ferrando et al., 
2002). In mouse models, the oncogenic NOTCH1 mutations have been shown to 
accelerate K-RAS induced transformation of normal T-cells (Chiang et al., 2008). 
Additionally, overexpression of NICD1 and NICD3 has been shown to lead to T-cell 
lymphoma formation (Aster et al., 2000, Izon et al., 2001, Pear et al., 1996). Notch has 
also been shown to be oncogenic in other contexts, such as breast cancer and melanoma 
(Koch and Radtke, 2007, Pinnix and Herlyn, 2007). Notch activates pathways involved in 
the initiation of these tumor types, including AKT and NF-κB (Liu et al., 2006, Bedogni et 
al., 2008, Osipo et al., 2008), and has been shown to have a role in maintaining cancer 
stem cells (Fan et al., 2010, Wang et al., 2011). However, Notch activation has also been 
linked to tumor suppressive functions in some cancers, especially in skin squamous cell 
carcinoma where Notch1 activates tumor suppressor p21 (Rangarajan et al., 2001). Taken 
together, Notch has a pivotal role in tumor formation depending on the type of the 
malignancy, genetic landscape, and mechanisms that are still inadequately understood.  
 
2.1.3.1.2$Notch$in$angiogenesis$and$mesenchymal$transitions$
In addition to the direct effects on the tumor cells and stem cells, Notch signaling plays an 
additional role in regulating normal and tumor angiogenesis (Benedito and Hellstrom, 
2013). ECs express Notch1, Notch2, and Notch4, as well as ligands Dll1, Dll4, and Jag1 
(Kofler et al., 2011). The importance of the activated Notch in developmental 
angiogenesis is elucidated by genetic knockout experiments, in which loss of Notch1, 
Hey1/2, or Rbp-jκ has led to embryonic lethality due to defects in sprouting angiogenesis 
(Fischer et al., 2004, Krebs et al., 2004, Krebs et al., 2000). Dll4 and Notch levels are 
interchangeably regulated by the VEGF-VEGFR2 axis. This arrangement is needed to 
give rise to appropriate numbers of VEGF responsive cells, organized angiogenesis, and 
finally functional vessels (Jakobsson et al., 2010). In the tumor vasculature, the inhibition 
of Dll4/Notch1 axis has been accordingly shown to suppress tumor growth by giving rise 
to hyper dense immature vascular network of non-functional vessels (Noguera-Troise et 
al., 2006, Ridgway et al., 2006).  
 
Besides the ECs, Notch regulates the vessel mural cells, which play a supportive role in 
normal and pathological angiogenesis (Benjamin et al., 1998). Notch3 has been shown to 
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be necessary for the maintenance of the mural cells (Domenga et al., 2004, Liu et al., 
2010), and to be induced by Jag1 expressed by the ECs (Liu et al., 2009). In addition, 
activated Notch can upregulate PDGFR-β expression leading to enhanced mural cell 
recruitment (Jin et al., 2008). Dll4 is then needed in the bone-marrow recruited cells to 
express pericyte/vascular smooth muscle cell markers (Stewart et al., 2011).  Furthermore, 
Notch activation has been shown to promote EndMT and EMT by directly upregulating 
PDGFR-β and α-SMA (Jin et al., 2008, Noseda et al., 2006), the EMT/EndMT 
transcription factors Snail and Slug (Niessen et al., 2008, Sahlgren et al., 2008), and 
repressing E-cadherin gene expression (Becker et al., 2007, Leong et al., 2007). 
Additionally, Notch dependent transcription factors Hif-1α, Msx1, Sox9, and Stat4 were 
shown to drive EndMT in cardiac valve development (Chang et al., 2014). Notch also 
interacts with other pathways, such as TGF-β, in inducing EMT/EndMT. TGF-β has been 
shown to induce Notch ligands (Niimi et al., 2007), and TGF-β induced EMT can be 
blocked by Notch inhibition (Zavadil et al., 2004). 
    
2.1.3.2$Nuclear$factor$kappa$B$(NF3 B)$pathway$
Nuclear factor kappa B, NF-κB, transcription factor family regulates inflammation and 
cancer in a complex manner and consists of five members including p65 (RelA) (Hoesel 
and Schmid, 2013).  These factors form homo- or heterodimers, and in quiescent cells they 
are bound to inhibitors of the IκB family (May and Ghosh, 1997). The NF-κB gene 
expression activation requires upstream kinase signaling that leads to IκB phosphorylation 
and ubiquitinylation, release of the transcription factors from the inhibitors, and shift of 
the transcription factor dimers to the nucleus (Hayden and Ghosh, 2008). The kinase 
cascade is initiated by the ligand binding of membrane bound receptors, including Toll-
like receptors (TLRs) stimulated by microbial components, interleukin 1 (IL-1) receptor, 
and TNF receptor (Schmid and Birbach, 2008). When the NF-κB transcription factors 
bind DNA, it leads to transcription of the target genes, including anti-apoptotic genes such 
as Bcl-2, cytokines including IL-1 and IL-6, as well as adhesion molecules such as 
VCAM-1 and ICAM-1 (Hoesel and Schmid, 2013). Different dimers have different DNA 
binding preferences, which can be altered by post-translational modifications such as 
phosphorylation (Oeckinghaus and Ghosh, 2009). For example, serine 536 (S536) 
phosphorylation of p65 has been shown to stimulate its transcriptional activity and 
stability, as well as decrease its nuclear export (Bohuslav et al., 2004, Delhase et al., 2012, 
Lawrence et al., 2005). These phosphorylations serve as points of crosstalk with other 
signaling pathways, such as the mitogen-activated protein kinase (MAPK) pathway 
(Schulze-Osthoff et al., 1997). Furthermore, NF-κB members both positively and 
negatively interact with other transcription factors, such as STAT3 and p53, as well 
(Grivennikov and Karin, 2010, Webster and Perkins, 1999).  
 
Diverse mechanisms can lead to constitutively active NF-κB in tumors. These include 
direct mutations, oncogene mediated activation, and tumor microenvironment secreting 
cytokines. In some hematopoietic malignancies, it has been seen that oncogenic p65 
mutations can drive the tumorigenesis (Courtois and Gilmore, 2006). In contrast, in many 
solid tumors, NF-κB activity is maintained by constitutive flux of cytokines from tumor-
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associated macrophages (Hagemann et al., 2008). The role of NF-κB in cancer is 
multidimensional, as it can be both anti- and pro-tumorigenic (Hoesel and Schmid, 2013). 
By mediating acute inflammatory response, its activation can lead to cytotoxicity towards 
tumor cells (Disis, 2010). However, experiments on genetically modified mice suggest 
that active NF-κB has a role in the survival of various tumors. For example, N-Ras 
induced mouse melanoma initiation required IKK2-mediated NF-κB activation (Yang et 
al., 2010). The constitutive activation of NF-κB seen in many tumors can act in a 
protumorigenic manner via multiple mechanisms. In addition to innate immunity, NF-κB 
activation is linked to increased survival by regulating cell proliferation and apoptosis 
(Guttridge et al., 1999, La Rosa et al., 1994). NF-κB has also been shown to control EMT 
and upregulate VEGF, leading to increased angiogenesis, invasion and metastasis (Huber 
et al., 2004, Xie et al., 2010), as well as to stimulate lymphangiogenesis (Flister et al., 
2010, Ji, 2014). 
$
2.2$TUMOR3STROMA$INTERACTIONS$$
2.2.1$The$pivotal$role$of$cancer$associated$fibroblasts$(CAFs)$$
Cancer associated fibroblasts (CAF) are activated fibroblasts residing within the tumor. 
They share similar properties with fibroblasts involved in inflammation and wound 
healing (Madar et al., 2013). They express a variety of activated stromal cell markers such 
as FSP-1, fibroblast activating protein (FAP), vimentin, and α−SMA, as well as receptors 
for the PDGFs (Augsten, 2014). However, none of these markers is specific for the CAFs 
as the wide variety of normal fibroblasts and other stromal cells also express some of these 
markers, which makes distinguishing between these cells difficult (Madar et al., 2013). 
The diverse origin of CAFs contributes to their heterogeneity. CAFs can arise from tissue-
resident fibroblasts stimulated by the tumor cells, recruited bone marrow cells (BMCs), or 
through EMT/EndMT (Elkabets et al., 2011, Quante et al., 2011, Radisky et al., 2007, 
Zeisberg et al., 2007a). α−SMA-expressing pericytes and adipocytes have also been 
suggested as possible origins of CAFs (Bochet et al., 2013, Dulauroy et al., 2012, Goritz 
et al., 2011). 
 
The role of CAFs in promoting tumor progression is well established. They differ from 
normal fibroblasts as they are more proliferative and produce more collagen, and a myriad 
of cytokines, chemokines, and growth factors (Augsten, 2014). These affect in autocrine 
and paracrine manners, and promote tumor growth, invasion and EMT, as well as recruit 
other stromal cells such as ECs and immune cells (Orimo et al., 2005, Augsten et al., 
2009). In addition, CAFs are able to remodel the ECM by expressing matrix components 
and matrix-remodelling enzymes including MMPs (Spaeth et al., 2009, Sugimoto et al., 
2006). CAFs have shown tumor promoting potential in mice when they are recruited to the 
tumor site, when they are co-injected with tumor cells, or when the injected tumor cells 
are pre-conditioned by CAF media (Olumi et al., 1999, Suetsugu et al., 2011). CAFs 
promote tumor progression from premalignant phase, stimulate metastasis and support 
outgrowth of disseminated cells (Malanchi et al., 2012, Zhang et al., 2013).  However, the 
function of CAFs is context dependent, as they have also been shown to have tumor 
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suppressing functions (Chang et al., 2012, Green et al., 2013). It is plausible that the tumor 
cells and the tumor microenvironment modulate the function of CAFs and determine the 
CAF function and marker expression (Augsten, 2014).  
 
2.2.2$Endothelial$cells$as$tumor$regulators$
Lately, it has been recognized that ECs do not just form conduits for liquids and cells but 
can participate in regulating tissue homeostasis in various settings. Hu et al. showed that 
liver regeneration is regulated spatiotemporally by liver ECs. They produce different 
levels of ANG-2 depending on the phase of liver regeneration and coordinate hepatocyte 
and EC proliferation in response to injury (Hu et al., 2014). Furthermore, ECs have been 
described to both positively and negatively regulate the tumor cell survival and growth. 
Tumor ECs are important in the maintenance of glioblastoma stem cells via Notch 
signaling in 3D culture models (Hovinga et al., 2010), whereas endothelially expressed 
DLL4 has been shown to inhibit small cell lung cancer cell growth by activating Notch1 in 
the tumor cells (Ding et al., 2012). Additionally, tumor cell – EC interactions have been 
shown to modify their reciprocal adhesion properties. Tumor cells expressing CD44 
stimulate/upregulate E-selectin expression on the surface of ECs, which ultimately leads 
to expression of ICAM-1 on the surface of ECs. Upregulated ICAM-1 levels can in turn 
recruit neutrophils and assist melanoma cell adhesion to ECs, as well as enhance their 
migration (Zhang et al., 2014). Furthermore, ECs can express chemokines attracting tumor 
cells and thus enable metastasis to lymph nodes and distant organs. For example, 
chemotaxis towards lymphatics has been shown to be mediated by the interaction between 
LEC expressed CXCL12, CCL1, and CCL21 ligands and CXCR4, CCR8 and CCR7 
chemokine receptors expressed by many tumor cells (Cabioglu et al., 2005, Shields et al., 
2007, Das et al., 2013). The reciprocity and complexity of tumor cell – EC interactions are 
well demonstrated in studies by Lee and colleagues: they show that breast cancer secreted 
factor, IL-6, can condition lymphatic ECs at pre-metastatic sites by Stat3 phosphorylation 
in LECs. This leads to increased angiogenesis via HIF-1α and VEGF induction. 
Additionally, CCL5 expression is upregulated in the tumor conditioned LECs, leading to 
recruitment of tumor cells to metastatic sites and thus increased metastasis (Lee et al., 
2014a, Lee et al., 2014b). Furthermore, it has been recently shown that ECs can promote 
metastasis by recruiting tumor promoting immune cells to the pre-metastatic niche by 
secreting factors such as ANG-2, and that this can be attenuated by anti-ANG-2 therapy 
(Srivastava et al., 2014). 
 
2.2.3$Immune$system$in$tumor$progression$
In addition to CAFs and ECs, components of the immune system are important regulators 
of tumor initiation and progression. Immune cells can be either inhibitory for tumor 
growth or they can promote the tumors. Anti-tumorigenic cells include CD8+ T-cells and 
natural killer cells. It has been shown that high CD8+ T-cell count in some tumor types 
correlates with better prognosis (Azimi et al., 2012, Galon et al., 2006). However, 
established tumors hardly ever encounter immune system mediated rejection, suggesting 
that the tumor microenvironment in general is immunosuppressive (Gajewski et al., 2013). 
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Indeed, several mechanisms for immune evasion have been described. These include 
dysfunction of CD8+ T-cells, accumulation of regulatory T-cells, switching to inhibitory 
dendritic cell subsets, and immunosuppressive function of other stromal cells (Gajewski et 
al., 2013). Furthermore, macrophages can act as tumor promoters in primary tumors as 
well as in metastases (Noy and Pollard, 2014). The tumor associated macrophages 
(TAMs) are characterized by production of immunosuppressive molecules such as TGF-β 
and are able to inhibit effector immune cells by a myriad of other mechanisms as well 
(Noy and Pollard, 2014). TAMs can additionally contribute to tumor promotion by 
producing growth factors for the tumor cells (Goswami et al., 2005), TGF-β  secreted by 
them can induce EMT (Bonde et al., 2012), and they can promote angiogenesis and 
hematogenous metastasis by several mechanisms, including production of VEGF (Coffelt 
et al., 2009, Yeo et al., 2014). In the metastases, macrophages can aid tumor extravasation, 
promote tumor cell survival, induce angiogenesis, and inhibit cytotoxic T-cell function 
(Noy and Pollard, 2014).  
 
 
3.$NON3EPITHELIAL$SKIN$CANCERS$
3.1$ KAPOSI’S$ SARCOMA$ HERPESVIRUS$ (KSHV)$ AND$ ASSOCIATED$
MALIGNANCIES$
$
Kaposi’s sarcoma (KS) was first characterized by Moritz Kaposi in 1872 as an idiopathic 
pigmented sarcoma of the skin (Sternbach and Varon, 1995). It remained a rather rare and 
unknown entity until early 1980s, when its prevalence suddenly rose among the 
homosexuals of the US West Coast (Friedman-Kien, 1981). This led to a hypothesis of 
infectious origin of the disease, and KS was found to be linked to the human 
immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome 
(AIDS). However, it was not until 1994, when herpesvirus DNA was found from the KS 
lesions, that KSHV was discovered (Chang et al., 1994). Further studies showed that 
KSHV is necessary but not sufficient to cause the KSHV associated malignancies: KS 
(Chang et al., 1994, Moore and Chang, 1995), primary effusion lymphoma (PEL) 
(Cesarman et al., 1995a, Nador et al., 1995), and multicentric Castleman’s disease (Soulier 
et al., 1995). The genome of KSHV consists of double stranded DNA (dsDNA), and it 
belongs to the Gammaherpesvirinae subfamily of the Herpesviridae family. KSHV 
consists of capsid that contains the big genome, encoding more than hundred open reading 
frames (ORFs), surrounded by amorphous protein tegument and a lipid envelope (Neipel 
et al., 1998). The vast genome contains remarkable number of genes hijacked from the 
ancient host cells, including homologs of cyclin D, Flice inhibitory protein (FLIP), and G-
protein coupled receptor (Jarviluoma and Ojala, 2006), which has made it a valuable tool 
in cancer biology research. The consequences of the KSHV oncogene expression for 
regulating the virus replication, and the cancer hallmarks are summarized in Figure 5.  
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Figure$5.$KSHV$Replication$and$Persistence$Strategies.$
KSHV oncogenes, as well as cellular signaling pathways and cancer hallmarks that they 
regulate are shown in the upper panel. The cancer hallmarks are depicted by the color 
code in the lower table, which also shows the consequence for virus replication. DDR= 
DNA damage response (modified from (Mesri et al., 2014)). 
$
3.1.1$Virus$life$cycle$in$KSHV$pathogenesis$
Like other herpesviruses, KSHV exhibits two phases of infection: latency and lytic 
replication. In latency, the virus hides from the host immune system and only a few viral 
genes are expressed, namely latency associated nuclear antigen (LANA), viral homolog of 
FLIP (vFLIP), viral cyclin D homolog (v-cyclin), viral interferon regulatory factor 3 
(vIRF3), kaposin B, and the KSHV microRNAs (miRNAs) (Dittmer et al., 1998, Sin and 
Dittmer, 2013). In latently infected cells, the viral genome is found as a separate circular 
DNA, called episome. The episome is dividing together with the host genome during 
mitosis, as KSHV LANA keeps them attached together (Hu et al., 2002, Verma et al., 
2006). For the virus to rapidly replicate, the virus needs to enter the lytic phase of the life 
cycle by a process called reactivation. This can be initiated by physiological stimuli such 
as hypoxia or by chemicals affecting the epigenetic regulators of the host (Ye et al., 2011, 
Yu et al., 1999). In lytic replication, the whole viral genome is transcribed in an organized 
manner finally leading to production of new viral particles and lysis of the host cell (Sun 
et al., 1999).  
 
As KSHV is in latency in most tumor cells, and tumorigenesis is a time-consuming 
process, it has been thought that the latent genes are especially important in the 
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development of the cancer (Giffin and Damania, 2014). Supporting this, expressing the 
latency locus in mouse B-cells leads to plasma cell hyperplasia and lymphoma in a small 
subset of cases (Sin and Dittmer, 2013). Most of the latent KSHV genes have been shown 
to have oncogenic potential in in vitro cell models, and many of them also in transgenic 
mouse models. The cellular pathways affected are varied but involve pathways related to 
cell survival and growth (see Figure 5). For example v-cyclin is a viral D cyclin homolog 
(Chang et al., 1996), and LANA inactivates negative regulators of the cell cycle, p53 and 
pRb (Friborg et al., 1999, Radkov et al., 2000). vFLIP and miRNAs on the other hand 
have been shown to inhibit apoptosis (Liu et al., 2002, Suffert et al., 2011). vFLIP has also 
been shown to affect cell survival pathways, such as NF-κB (Guasparri et al., 2004, Keller 
et al., 2000). It is not surprising that latent viral genes affect these pathways, as it is crucial 
for the survival of the virus that the host cell stays alive as long as the virus is not 
replicating. Thus, the cancer appears to be rather a side effect of the viral life cycle. There 
is evidence of the oncogenicity of v-cyclin, vFLIP, and LANA in transgenic mouse 
models as well (Ballon et al., 2011, Fakhari et al., 2006, Verschuren et al., 2004a, 
Verschuren et al., 2002). However, some of the oncogenes, including K1, K15, viral G-
protein coupled receptor (vGPCR), viral IL-6 (vIL6), and viral Bcl-2 homolog (vBcl-2), 
are expressed only during the lytic phase (Giffin and Damania, 2014). The lytic cycle is 
additionally needed to infect new target cells in tumors, and it has been shown that 
increased lytic replication and viral load correlate with poor prognosis. Moreover, high 
lytic replication level has been shown to cause resistance to therapies (El Amari et al., 
2008, Nichols et al., 2011). Below, some of the most important viral oncogenes are 
introduced. 
$
3.1.1.1$v3cyclin$
The latent KSHV transcripts LANA, vFLIP and v-cyclin are transcribed from a common 
transcription start site. After splicing, LANA is expressed separately, but vFLIP and v-
cyclin are expressed from a common bicistronic message (Dittmer et al., 1998, Talbot et 
al., 1999). KSHV viral cyclin (v-cyclin) is a homolog of cellular cyclin D. At sequence 
level, it mostly resembles cyclin D2, but shares homology with cyclin D1 and D3 as well 
(Chang et al., 1996). It has been shown to bind to many different cyclin dependent kinases 
(CDK) in vitro, but all its functions known to date are mediated by CDK6 (see Figure 6). 
Similar to cyclin D-CDK6 interaction, the binding of v-cyclin with CDK6 leads to 
activated kinase function of CDK6 and phosphorylation of its targets, most notably the 
retinoblastoma protein (pRb), and G1 to S-phase cell cycle progression (Godden-Kent et 
al., 1997, Verschuren et al., 2004b). Furthermore, v-cyclin has functions beyond cyclin D. 
Together with CDK6, it can phosphorylate multiple targets of S-phase cyclin E-CDK2 
complex including histone H1, CDC6, ORC1 (Ellis et al., 1999, Laman et al., 2001, Mann 
et al., 1999), and Bcl-2 (Ojala et al., 2000). As the v-cyclin expression from the viral 
genome is constitutive, normal cell cycle regulation cannot control it. In addition, v-
cyclin-CDK6 can deregulate cell cycle by inactivating the cell cycle inhibitors p21 and 
p27 by specific phosphorylations (Ellis et al., 1999, Mann et al., 1999, Sarek et al., 2006, 
Swanton et al., 1997). Taken together, active v-cyclin-CDK6 complex leads to progression 
of cell cycle in a manner that is not controlled by the cellular regulation mechanisms. Like 
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other oncogenes, extensive v-cyclin expression without compensatory (viral) mechanisms 
leads to oncogene induced DNA damage response and senescence (Koopal et al., 2007), 
autophagy (Leidal et al., 2012), as well as cell cycle arrest and apoptosis (Koopal et al., 
2007, Ojala et al., 2000, Verschuren et al., 2002, Ojala et al., 1999).  Further proof for the 
oncogenic function of v-cyclin comes from the rat mesenchymal cell model, where v-
cyclin was shown to be needed for the KSHV induced transformation and post-confluent 
growth (Jones et al., 2014). v-cyclin was recently also shown to counteract the G1 cell 
cycle arrest caused by vFLIP and NF-κB hyperactivation (Zhi et al., 2014). In addition, 
transgenic mouse studies have shown that v-cyclin can act as an oncogene in the 
lymphocyte compartment, and this could be enhanced by p53 deficiency (Verschuren et 
al., 2004a, Verschuren et al., 2002). 
 
 
 
$
Figure$6.$Regulation$of$the$cell$cycle$by$KSHV$and$HPV.$
KSHV can regulate the G1-S cell cycle transition by encoding a homolog of cyclin D, v-
cyclin, which together with its kinase partner CDK6 is able to phosphorylate several 
substrates such as pRb. pRb phosphorylation by v-cyclin-CDK6 abolishes E2F inhibition 
by pRb and activates transcription of S-phase genes. Furthermore, v-cyclin-CDK6 can 
phosphorylate the cyclinE-CDK2 inhibitor p27Kip1, as well as S-phase substrates, 
including ORC1 and CDC6. KSHV encoded LANA can bind pRb, and thereby inhibit its 
function. All these changes promote G1-S transition of the cell cycle. Highlighting the 
conserved nature of cell cycle regulation by human tumor viruses, the HPV E7 protein is 
able to induce S-phase entry via several mechanisms, including pRb degradation and 
inactivation of cell cycle inhibitors. ℗=phosphorylation, (modified from (Boshoff and 
Weiss, 2002)). 
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3.1.1.2$vFLIP$
Viral FLICE inhibitory protein (vFLIP) is a homolog of caspase 8 promodomain, and 
contains two death effector domains (DED) (Liu et al., 2002).  Cellular and viral FLIPs 
block death receptor mediated apoptosis by preventing recruitment of caspase 8 to the 
death inducing signaling complex. However, KSHV vFLIP seems not to be able to inhibit 
Fas-mediated apoptosis in vivo (Chugh et al., 2005) but has unique function to inhibit 
apoptosis by inducing NF-κB. vFLIP binds to the IKK, which phosphorylates NF-κB 
inhibitor IκB leading to its degradation and finally releases the transcription factor dimer 
p50-p65 to bind DNA (Liu et al., 2002). In PEL cells, vFLIP mediated constitutional 
activation of NF-κB is essential for their survival and proliferation (Guasparri et al., 2004, 
Keller et al., 2000), and has been shown to require TNF receptor-associated factors 
TRAF2 and TRAF3 (Guasparri et al., 2006). vFLIP has also been shown to protect ECs 
from superoxide-induced cell death by upregulating manganese superoxide dismutase in 
NF-κB dependent manner (Thurau et al., 2009). In addition to NF-κB, vFLIP mediated 
increased survival has been linked to its ability to suppress autophagy by preventing Atg3 
from binding and processing LC3 (Lee et al., 2009). Several models have been developed 
to study the vFLIP in vivo. vFLIP expressed under H2Kb promoter and immunoglobulin 
heavy chain (Eµ) enhancer in mice leads to NF-κB activation both by the canonical and 
alternate pathways (Chugh et al., 2005). These mice show increased proliferation of the 
splenocytes and increased incidence of lymphoma (Chugh et al., 2005). In a more 
sophisticated B-cell mouse model, Ballon et al. showed that vFLIP expression in the 
germinal center B-cells leads to formation of multicentric Castleman’s disease like 
phenotype (Ballon et al., 2011). In ECs, vFLIP expression has been linked to the spindle 
morphology of the KSHV infected cells via NF-κB activity (Grossmann et al., 2006, 
Alkharsah et al., 2011). Furthermore, vFLIP has been shown to upregulate the expression 
of pro-inflammatory cytokines, chemokines, and interferon-responsive genes (Sakakibara 
et al., 2009, Thurau et al., 2009), and its depletion from the whole virus leads to reversion 
of Stat1-responsive gene activation and spindle cell morphology (Sakakibara et al., 2009).  
 
3.1.1.3$vGPCR$
An example of a KSHV oncogene expressed in the lytic phase is viral GPCR, which is a 
transmembrane protein sharing homology with the cellular IL-8 receptor (Cesarman et al., 
1996). It can be activated by chemokines belonging to the CXC and CC families, but it is 
also constitutively active autonomous from the ligand binding (Arvanitakis et al., 1997, 
Bais et al., 1998, Gershengorn et al., 1998). vGPCR increases cell survival by inducing 
MAPK, PIK3/Akt/mTOR, and NF-κB pathways. Downstream of these pathways, vGPCR 
expression upregulates several transcription factors, including activator protein 1 (AP1), 
NFAT, NF-κB, HIF-1α, and cAMP-responsive element binding protein (CREB), leading 
to expression of VEGF and several pro-inflammatory cytokines and chemokines 
(Montaner, 2007).  In ECs, this leads to increased proliferation and angiogenic potential in 
vitro (Bais et al., 2003, Montaner et al., 2001, Sodhi et al., 2006). In mouse models, 
transgenic vGPCR expression under an endothelial cell promoter has led to formation of 
angiogenic tumors dependent on AKT and mTOR (Montaner et al., 2003, Sodhi et al., 
2006, Sodhi et al., 2004b). Furthermore, siRNA mediated depletion of vGPCR from the 
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whole virus led to decreased tumorigenic and angiogenic potential in vivo (Mutlu et al., 
2007). 
 
3.1.2$Kaposi’s$sarcoma$
KS is divided into four clinico-epidemiological forms depending on the affected 
population: classic KS, endemic (African) KS, AIDS associated (epidemic) KS, and 
iatrogenic KS (Antman and Chang 2000). The classical KS described by Moritz Kaposi is 
manifested in the lower extremities of elderly Mediterranean men and usually has indolent 
natural progression. The endemic KS is found in equatorial Africa and shows a more 
aggressive behavior. The AIDS associated KS is usually very aggressive and is associated 
with advanced HIV infection usually accompanied by low CD4+ T-cell counts. The use of 
highly active antiretroviral therapy (HAART) has decreased the prevalence of AIDS-
associated KS, but some cases seem refractory for the HAART treatment, and some cases 
have been described in patients with low HIV copy numbers and high CD4+ T-cell counts 
(La Ferla et al., 2013). The iatrogenic KS is seen in immunocompromised patients mostly 
after organ transplantations. KSHV infection is required for development of all forms of 
KS, and KSHV seroprevalence geographically correlates with the amount of KS cases, 
being especially high in Africa and in the Mediterranean region. In Finland, KSHV 
seroprevalence is low (estimated to be 1%), and the incidence of KS is 0.1-0.2 per 100 000 
person-years in 1963-2010, age-adjusted to the World Standard Population (Aavikko, 
2014, http://www.cancer.fi/syoparekisteri/). As not all KSHV infected individuals develop 
KS, additional factors are needed for the development of the disease. These include 
compromised immune system, other infections such as HIV and malaria (Conant et al., 
2013), and local inflammatory milieu. However, the detailed mechanisms of the 
association/connection of KSHV and other factors still need further studies. 
 
KS manifests as red to purple nodules or plaques on the skin. Later in its clinical 
progression, it can also affect mucosa of the mouth and visceral organs. The clinical 
staging is based on the amount of the lesions, and the extent of the spread to these 
different body sites. The individual lesions are thought to progress from early, flat patch 
lesions into raised plaques, and finally form tumor nodules. Histologically, the patch 
lesions consist of abnormal vessels, sparse chronic inflammatory cells, extravasated red 
blood cells and hemosiderin-loaded macrophages (Radu and Pantanowitz, 2013). In the 
plaque lesions, both the vessels and spindle cells are proliferating. The main component of 
the tumor nodules is the KSHV infected tumor cells, called spindle cells because of their 
morphology. In addition, the nodules exhibit a vast stromal component, comprising of 
chronic inflammatory cells and abundant hemosiderin-loaded macrophages (Radu and 
Pantanowitz, 2013). The spindle cells express markers of blood (CD31, CD34) and 
lymphatic (podoplanin, LYVE-1, VEGFR-3, Prox-1) endothelial cell lineages (Dupin et 
al., 1999, Kaaya et al., 1995), as well as markers of smooth muscle cells and fibroblasts 
(Kaaya et al., 1995, Sturzl et al., 1995, Weich et al., 1991), so the exact origin of these 
cells is not known. However, the prevailing view suggests of an endothelial origin 
(Ganem, 2010). Supporting this, especially the LECs are prone to KSHV infection in vitro 
and can be used as tools to model the infection cascade ex vivo (McAllister and Moses, 
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2007, Aguilar et al., 2012).  Furthermore, it has been shown that KSHV infection can lead 
to transdifferentiation of BECs to LECs and vice versa, explaining the diversity of 
endothelial markers seen in the KS tumors (Carroll et al., 2004, Hong et al., 2004, Wang 
et al., 2004).  
 
The mechanisms by which KSHV is causing KS are not fully understood despite 
extensive research. It is known that the KSHV genome contains multiple possible 
oncogenes and that viral genes can also affect cellular tumor suppressors (Jarviluoma and 
Ojala, 2006) (Figure 5, see above). However, much of the data comes from models of 
primary effusion lymphoma rather than KS, or are studies based on expression of one gene 
rather than in the context of the whole virus. As the isolated KS tumor cells lose the 
episomal genomes of KSHV upon culture (Grundhoff and Ganem, 2004), they cannot be 
used as models of KS tumor cells. Studying the development of KS by de novo KSHV 
infection has also proven difficult, as KSHV infection per se does not lead to 
transformation in cell models. In fact, the ECs respond to KSHV infection initially rather 
by a growth arrest and senescence than increased proliferation (Koopal et al., 2007, 
Lagunoff et al., 2002). However, this might be time dependent, as Wang and Damania 
showed that KSHV induced the PI3K/Akt/mTOR pathway and increased the survival and 
angiogenic potential of the human umbilical endothelial cells (HUVEC) after several 
weeks of culture when the culture was under selection for infected cells (Wang and 
Damania, 2008). This is supported by data showing that mTOR inhibitor rapamycin has 
an impact in treating KS both in the clinic and in a mouse model (Roy et al., 2013, Nichols 
et al., 2011). In addition, KSHV has been reported to activate the Notch pathway linked to 
tumorigenesis, angiogenesis, and differentiation in LECs via vFLIP and vGPCR mediated 
activation of Notch ligands Jag1 and Dll4. This was further shown to lead to 
downregulation of cell cycle components in the neighboring uninfected cell, giving the 
infected cells a growth benefit (Emuss et al., 2009). 
 
Modeling the role of KSHV infection in the development of KS in mouse models has been 
challenging as well, since KSHV does not easily infect rodent cells. However, recently 
several attempts have been successful. Mutlu et. al showed that transfecting KSHV 
bacterial artificial chromosome (KSHVBAC36) into mouse bone marrow endothelial 
precursor cells can transform them and lead to KS like tumor formation in mice. In this 
model, siRNA suppression of vGPCR leads to reduced angiogenesis and tumorigenesis 
(Mutlu et al., 2007). In addition, it has been shown that KSHV can transform rat 
mesenchymal stem cells and lead to tumor formation in vivo (Jones et al., 2012).  To study 
the role of individual genes in this system, Jones et al. deleted viral genes individually. 
Using this approach they were able to show that v-cyclin expression was needed to drive 
oncogenesis and override contact inhibition (Jones et al., 2014). Further suggesting that 
rodent progenitor cells can be infected, Ashlock et al. showed that mouse bone marrow 
derived progenitor cells could be infected by recombinant KSHV, and these cells could 
give rise to tumors in mice (Ashlock et al., 2014). Moreover, humanized NOD/SCID/IL2γ 
mice were shown to be susceptible for KSHV infection through natural infection routes, 
possibly providing a model system to study KSHV pathogenesis in future (Wang et al., 
2014).  
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3.1.3$Primary$effusion$lymphoma$(PEL)$
KSHV associated PEL is a very rare but aggressive form of HIV-associated non-
Hodgkin's lymphoma that accounts for 4% of the cases. The median survival after 
diagnosis is only six to nine months (Boulanger et al., 2005). PEL is almost exclusively 
detected in KSHV positive HIV infected individuals, and the lymphoma cells may be co-
infected with EBV (Cesarman et al., 1995a, Cesarman et al., 1996, Nador et al., 1996). 
PELs are characterized by proliferation of lymphoid cells in pleural, peritoneal, and 
pericardial effusions, and they typically do not form a solid tumor mass. The lymphoma 
cells exhibit “null” lymphocyte phenotype as they express the common lymphocyte 
marker CD45, but not markers for B-cells (CD19, CD20, CD79a or surface 
immunoglobulins) or T-cells (CD3, CD4, CD8).  However, they do express markers of 
plasma cell differentiation (CD138) and activated lymphocytes (CD30, CD38, CD71). 
Immunogenotypic studies usually show immunoglobulin gene rearrangements and 
somatic hypermutations, suggesting a post-germinal center B-cell origin (Klein et al., 
2003).  This is supported by in vitro observations, showing that even though B-cells are 
not readily infectable by KSHV, successful B-cell infection drives them towards 
plasmablast differentiation (Hassman et al., 2011). In contrast to KS cells, PEL cells retain 
viral genomes in culture, and tumor cell lines can be obtained (Arvanitakis et al., 1996, 
Cesarman et al., 1995b). Moreover, when injected subcutaneously or intraperitoneally into 
mice, the PEL cells form tumors (Dai et al., 2014).  
 
Many viral factors and cellular signaling pathways have been linked to the growth and 
survival of the PEL cells. PEL cells have been shown to be dependent on vFLIP induced 
NF-κB activation in vitro and in vivo (Guasparri et al., 2004, Keller et al., 2000). In 
addition, there have been reports showing that PEL cells are dependent on Notch 
signaling, as the gamma secretase inhibitor DAPT treatment leads to cell cycle arrest and 
apoptosis of PEL cells in vitro and in vivo (Lan et al., 2009). One mechanism by which 
KSHV is activating Notch in PEL cells is LANA mediated stabilization of NICD1 (Lan et 
al., 2006, Lan et al., 2007). Furthermore, several viral and cellular cytokines, including 
viral IL-6, IL-6, IL-10, stromal cell-derived factor 1, and VEGF have been shown to be 
important for the PEL cell survival and growth (Gasperini et al., 2008). 
 
 
3.2$MELANOMA$
Melanoma is a cancer of melanocytes, the pigment producing cells of the skin and 
mucosa. Clinically it appears as pigmented macules, and should be suspected if changes in 
size, color, or symmetry appear in pre-existing melanocytic lesions or new lesions arise at 
older age (Muller, 2014). Melanoma comprises four percent of all cancers, and 
approximately 1200 cases are diagnosed yearly in Finland 
(http://www.cancer.fi/syoparekisteri/). The incidence of melanoma is rising in Caucasian 
populations and most steeply in young women, possibly because of increased UV 
radiation to previously protected areas of the body (Rastrelli et al., 2014). Due to its poor 
prognosis after metastatic spread, it is the most notorious of all skin cancers, even though 
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the combined 5-year survival rate was 84% of male and 89% of female patients in Finland 
in 2012 (http://www.cancer.fi/syoparekisteri/). The risk factors of melanoma include both 
genetic, most notably fair skin, and environmental factors such as extensive UVB/A 
radiation. Even though the sun exposure is considered the main risk factor for the onset of 
melanoma, its role is complex. The most commonly affected sites in light skinned persons 
are in fact the areas that are exposed to sun intermittently, not chronically, and melanoma 
can arise also in mucosal membranes and acral sites, which are not exposed to sun 
(Whiteman et al., 2001).  
 
Melanomas are divided into clinicopathological subtypes, the most common types being 
lentigo maligna melanoma, superficially spreading melanoma, and nodular melanoma 
(Muller, 2014). These types follow the widely accepted concept of radial and vertical 
growth phases in melanoma progression. In radial growth phase, the tumor cells are found 
intraepidermally as flat circles of pigmented cells, whereas the vertical growth phase is 
characterized by tumor cells infiltrating the dermis (Chin, 2003). Angiogenesis and 
expression of vascular growth factors are also associated with the progression to the 
vertical growth phase (Braeuer et al., 2011). Superficially spreading melanoma shows first 
radial growth phase and only after a long period of time shows invasion into deeper 
tissues. In contrast, nodular melanoma starts the vertical growth phase early in its history, 
and thus has a poorer prognosis.  
 
3.2.1$Melanoma$initiation$
The most common genetic alteration in melanocytes leading to their transformation is an 
activating BRAF mutation caused by an amino acid substitution from valine (V) to 
glutamate (E) at codon 600 (refered as V600E) (Davies et al., 2002, Curtin et al., 2005). 
This mutation can be seen in 50% of the melanoma patients, and leads to activation of 
MAPK signaling. Mechanistically, the autonomous activation in BRAF leads to 
phosphorylation of MEK and ERK, and finally activation of cyclin D1-CDK4/6 complex 
and progression of the cell cycle. In cases where BRAF is wild type, its upstream regulator 
N-RAS is commonly (20% of cutaneous melanomas) mutated, leading to the activation of 
the same pathway. Especially in mucous melanomas, the receptor tyrosine kinase c-KIT, 
which is affecting the same downstream pathways, is often mutated. In cases where these 
regulators are not affected, the downstream effector cyclin D1 gene CCND1 and its kinase 
partner CDK4 gene regions are commonly amplified (Curtin et al., 2005). The cell cycle 
inhibitor p16 gene CDKN2A locus is the most commonly deleted region (50%) in 
melanoma further highlighting the importance of this pathway (Curtin et al., 2005). 
Moreover, the PI3K pathway inhibitor PTEN is commonly deleted in BRAF mutant but 
not in N-RAS mutant melanomas, suggesting that the MAPK and PI3K work in parallel 
downstream of RAS to promote melanoma formation.  
 
3.2.2$Melanoma$progression$
Even though the MAPK pathway is the major driver of melanoma growth, the pathways 
leading to tumor progression and metastasis are more widespread. This is important to 
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notice as virtually all deaths associated to melanoma are due to metastases. More than 
95% of patients who initially have early stage disease are cured from melanoma by 
surgery, whereas the 5-year survival rate of patients with visceral metastases is less than 
10% (Balch et al., 2009). Treatments of advanced melanoma that have been concentrating 
on inhibition of the MAPK pathway first seemed beneficial, but patients soon developed 
resistance to them. The most commonly used targeted therapy has been veramurafenib, a 
BRAF inhibitor, which has shown good response for 6-9 months (McArthur et al., 2014), 
but then the BRAF inhibition has been bypassed by activated RAS. Combination of BRAF 
inhibitors with MEK inhibitors have led to a prolonged progression free survival from 6.3 
months to 11 months, but has as well been curative only in very few patients (Larkin et al., 
2014). Furthermore, in some contexts these inhibitors might even be promoting the 
metastasis. It was recently shown that BRAF/MEK inhibitors can increase the invasive 
potential of 20% of the melanoma cell lines by regulating STAT3 (Vultur et al., 2014). 
Thus, understanding the mechanisms of melanoma metastasis is crucial for developing 
better treatments.  
 
The best-studied prognostic factors considering the primary tumor are tumor thickness and 
ulceration, highlighting the importance of the transition from the radial to vertical growth 
phase. It is accompanied by molecular events including the loss of adhesive molecules and 
increased expression of proteases such as MMPs, leading to increased invasiveness 
(Villanueva and Herlyn, 2008, Moro et al., 2014). This might be due to deregulated 
expression of multiple transcription factors, including AP-2a, CREB, and NF-κB (Mobley 
et al., 2012). Other mechanisms that control the tumor progression are the pathways 
conducting tumor cell differentiation and plasticity, which in turn enable the tumors to 
interact and adapt to the tumor microenvironment (Hendrix et al., 2003). It has recently 
been shown that hypoxia can induce phenotypic plasticity in melanoma via activation of 
the tyrosine kinase receptor ROR2 (O'Connell et al., 2013). Furthermore, aggressive 
undifferentiated melanoma cells express Nodal, an embryogenic morphogene, which has a 
key role in regulating melanoma cell plasticity by mediating SMAD2 and SMAD3 
phosphorylation (Hendrix et al., 2007, Topczewska et al., 2006). The Nodal phenotypes 
have been shown to be regulated by Notch4 expression, suggesting that these two 
embryonal pathways are interacting and together regulate the melanoma cell plasticity 
(Hardy et al., 2010). The other Notch receptors have also been shown to be involved in the 
melanoma progression, as Notch1 has been shown to act as an effector of AKT signaling 
(Bedogni et al., 2008), whereas Notch2 induces invasion in uveal melanoma (Asnaghi et 
al., 2012), and Notch3 has been shown to be upregulated by EC interaction (Howard et al., 
2013).  
 
Lymphatic involvement has significance as a prognostic factor of melanoma. If only 
microscopic lymph node metastases are found (stage TxN1aM0), the 5-year survival is 
approximately 70%, while in the group of abundant lymph node metastasis (stage 
TxN3N0) it decreases to 30% (Balch et al., 2009). In addition, the primary tumor 
lymphatic vessel density, the relative area of lymphatic vessel invasion and the VEGF-C 
expression levels correlate with the metastases and poor prognosis (Dadras et al., 2005, 
Dadras et al., 2003). However, it is inadequately understood how the lymphatic 
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involvement regulates the melanoma distant metastasis and prognosis, as the removal of 
the metastatic lymph nodes has no survival benefit (Alitalo and Detmar, 2012, Sleeman et 
al., 2011). It is known that melanoma can directly, or indirectly through the immune cells, 
lead to VEGF-C expression in the tumors, and induce lymphangiogenesis (Peppicelli et 
al., 2014, Peppicelli et al., 2013). In addition, the chemokine ligand-receptor pairs have 
been shown to be important in the chemotaxis of the tumor cells towards the lymphatics 
(Cabioglu et al., 2005, Shields et al., 2007, Das et al., 2013). The specific tumor homing to 
different tissues, including skin and soft tissues followed by lung, liver, brain, bone, and 
basically all other organs, has been suggested to be also due to chemokine ligand-receptor 
binding (Kakinuma and Hwang, 2006). Examples include the CCR7/CCL21 axis, which 
has been linked to lymph node metastasis, whereas the CXCR4/ CXCL12 axis has been 
shown to be involved in liver, lung, and bone marrow metastasis (Raffaghello et al., 
2009). 
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AIMS$OF$THE$STUDY$
 
Tumor cells in both KSHV associated malignancies and melanoma exhibit features of 
cellular plasticity. Even though Kaposi’s sarcoma (KS) is thought to be of endothelial 
origin, KS tumor cells express markers of many lineages, including blood and lymphatic 
vasculature as well as smooth muscle cells and fibroblasts. In addition, the KSHV 
associated primary effusion lymphoma (PEL) has an undifferentiated plasma cell 
phenotype. Melanoma cells, on the other hand, have been shown to be able to undergo 
vascular mimicry, as well as to interact with the blood and lymphatic endothelial cells 
during cancer progression. The aim of this study is to understand what changes in the 
differentiation state or cellular reprogramming are involved in the pathogenesis of KS, 
PEL, and melanoma, and what the potential molecular mechanisms behind these events 
are. Specifically, the aims are: 
 
1. To study KSHV oncogene v-cyclin mediated oncogenesis mechanisms in the 
lymphocyte compartment in vivo  
 
2. To untangle the mechanism behind diverse expression of lineage markers in KS 
tumor cells 
 
3. To study if the lymphatic endothelial cell - tumor cell interactions lead to 
reprogramming and contribute to tumor progression in melanoma 
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MATERIALS$AND$METHODS$
1.$Mouse$experiments$(I,$II,$IV)$
All mouse lines used in the studies and their references are described in Table 1. Briefly, 
v-cyclin construct containing double flag-tag was expressed under the immunoglobulin 
heavy chain promoter/enhancer Eµ, which directs the expression to the lymphocyte 
compartment. These mice were bred into the outbred ICR (CD1) mouse background for at 
least five generations to generate the ICR- Eµ-v-cyclin line, or backcrossed to the inbred 
C57BL6 background for at least five generations to generate the BL6- Eµ-v-cyclin line. 
To test the tumorigenicity and metastatic capacity of the melanoma cells, the control 
Bowes and WM852 cells, as well as the same melanoma cells primed with primary LECs, 
were injected subcutaneously (s.c.) into immunocompromised C.B-17/IcrHanTMHSD-
Prkdc Scid (SCID) mice. The melanoma cells contained a double eGFP-luciferase 
reporter, enabling the in vivo imaging of the luciferase signal (Caliper IVIS Kinetic 
System) from the tumors and metastases. All mouse experiments were approved by the 
Finnish National Animal Experiment Board (license numbers: ESLH-2005-03350/Ym-23, 
ESLH-2006-04075/Ym-23, ESLH-2009-02139/Ym-23, ESAVI/434/04.10.03/2012). 
 
Table 1. Mice used in this study. 
background description source/reference used in 
C.B-
17/IcrHanTMHSD-
Prkdc Scid 
mice having severe combined immunodeficiency, 
i.e., lacking functional T- and B-cells 
Harlan 
Laboratories 
IV 
C57BL6 inbred mouse line Harlan 
Laboratories 
I 
C57BL6-Eµ-v-
cyclin 
v-cyclin transgene under Eµ promoter/enhancer in 
C57BL6 mouse background 
Publication I I 
CBA/C57BL6-Eµ-
v-cyclin 
v-cyclin transgene under Eµ promoter/enhancer in 
mixed mouse background 
(Verschuren et al., 
2004a, Verschuren 
et al., 2002) 
I 
Eµ-Myc c-Myc transgene under Eµ promoter/enhancer (Adams et al., 
1985) 
I 
ICR (CD1) outbred mouse stock Harlan 
Laboratories 
I, II 
ICR-Eµ-v-cyclin v-cyclin transgene under Eµ promoter/enhancer 
bred to ICR strain 
Publication I I, II 
 
2.$Cell$lines$(I,$II,$III,$IV)$
The cell lines used are listed in Table 2, and the culture conditions are described in the 
given references. In short, for the lymphoma cell lines generated in publication I, 
lymphoma tissues were disaggregated by pressing through a 70-µm nylon mesh cell 
strainer (BD Falcon) to obtain a single cell suspension. The isolated lymphoma cells were 
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cultured in lymphoma cell media (Schmitt et al., 2002) at density between 2x105 to 107 
cells/ml and grown for at least three passages before further analysis. 
 
Table 2. Cell lines used in this study.   
cell line description source/reference used in 
BC-3 PEL cell line  NIH AIDS Reagent 
Program 
II 
BCBL-1 PEL cell line NIH AIDS Reagent 
Program 
I, III 
BEC primary blood endothelial cells Promocell IV 
Bowes melanoma cell line (superficially spreading) Dr. Kaisa Lehti IV 
E -myc thymus 
lymphoma 
cell line from Eµ-Myc thymus lymphoma Dr. Anna Cvrljevic I 
HEK293 Human Embryonic Kidney 293 cells Biomedicum Functional 
Genomics Unit 
I, II, III 
HEK293A HEK293 cells, adherent clone Dr. Markus Vähä-
Koskela 
I 
HEK293-FlipIn HEK293 cell line designed for rapid 
generation of stable cell lines 
Invitrogen I 
LEC primary lymphatic endothelial cells from 
juvenile foreskin 
Promocell III, IV 
 primary lymphatic endothelial cells from 
adult skin 
Lonza IV 
Phoenix Ampho second generation retrovirus producer line  III, IV 
U2OS human osteosarcoma cell line   III 
v-cyc1 thymus 
lymphoma 
cell line from Eµ-v-cyclin mouse thymus 
lymphoma 
Publication I I 
v-cyc1 spleen 
lymphoma 
cell line from Eµ-v-cyclin mouse spleen 
lymphoma 
Publication I I 
v-cyc1 lymph 
node lymphoma 
cell line from Eµ-v-cyclin mouse lymph 
node lymphoma 
Publication I I 
v-cyc2 thymus 
lymphoma 
cell line from Eµ-v-cyclin mouse thymus 
lymphoma 
Publication I I 
v-cyc2 spleen 
lymphoma 
cell line from Eµ-v-cyclin mouse spleen 
lymphoma 
Publication I I 
v-cyc3 thymus 
lymphoma 
cell line from Eµ-v-cyclin mouse thymus 
lymphoma 
 Publication I I 
WEHI-3B mouse B-cell lymphoma line Dr. Anna Cvrljevic I 
WM852 melanoma cell line (skin metastasis) Dr. Kaisa Lehti IV 
$
3.$Cell$culture$models$(III,$IV)$
3.1$2D$co3culture$of$melanoma$and$endothelial$cells$(ECs)$
For physical co-culture, melanoma and LECs were seeded together on fibronectin (Sigma) 
or gelatin pre-coated cell culture plates in 1:1.5-1:3 ratio in endothelial cell culture media 
(EGM-2, Lonza), whereas similarly treated single-cultured cells served as controls. After 
48-72 h, the cells were either fixed for stainings or separated. For cell separations, the 
melanoma cells were pre-labeled with 1mg/ml fluidMAG-DX (Chemicell) magnetic beads 
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before the co-culture. The actual separations were done using the MidiMACS separator 
and LS column (both from Miltenyi Biotec), and collecting both the non-labeled (LEC) 
and labeled (melanoma) fractions for further use for immunofluorescent stainings, RNA 
lysates, or functional assays. To study the adhesion properties after the co-culture, the co-
cultured or single-cultured cells were seeded on top of a confluent layer of LECs, and 
allowed to interact for 12 h before fixation for stainings. To study the supernatant 
mediated effects, conditioned media experiments were used. Briefly, the LECs were 
cultured in the endothelial media for 24-48 h before collection of the supernatant, which 
was deprived for cells by filtering. The melanoma cells were incubated with the 
conditioned media for 24-72 h before fixation for stainings, or collection for RNA or 
protein lysates.  
 
3.2$2D$cell$migration$assay$
Cell migration in 2D was studied by using wound healing assay. Briefly, 5x104 melanoma 
or LEC cells in 70 µl of endothelial media were plated homo- or heterotypically on Ibidi 
inserts on 12-well plates coated with fibronectin, and let to attach for 12 h. Following the 
removal of the insert, the plates were immediately transferred to Cell IQ automated phase 
contrast microscope (CM Technologies; time point 0 h), and the wells were followed for 
48 h at 30 min intervals, during which the wound was fully closed in all samples.  
 
3.3$Fibrin$embedded$cultures$
Monolayers of BECs, LECs, or KSHV infected LECs (K-LEC) were seeded onto 0.5% 
agarose pre-coated, non-adherent round-bottom 96-well plates at 4000 cells per well. After 
16-24 h incubation at 37°C, the spontaneously formed spheroids were harvested and 
embedded into the fibrin gel consisting of plasminogen-free fibrinogen (final 
concentration 3-5 mg/ml; Calbiochem) and thrombin (final concentration 2 U/ml; Sigma) 
in Hank’s Balanced Salt Solution supplemented with aprotinin (200 µg/ml; Sigma). When 
co-cultured with the melanoma cells, the EC spheroids were mixed with 5000-10000 
melanoma cells prior to adding the fibrinogen and the enzymes. For fibrin invasion assay, 
single-cultured or 2D co-cultured melanomas were embedded at density of 5000 cells/gel. 
After complete gelling, culture medium containing 50-100 µg/ml aprotinin was added on 
top of the gels to prevent gel dissolving, and they were followed for 2–5 days. 
 
3.4$Quantification$of$spheroid$sprouting$
Quantification of spheroid sprouting was performed from the phase contrast or fluorescent 
images. From the phase contrast images, the sprouts and the spheroid body boundaries 
were depicted using the Inkscape software [http://www.inkscape.org]. The vector graphic 
data was first rendered with Inkscape, and then analyzed in a pipeline generated using the 
Anduril framework (Ovaska et al., 2010). This pipeline searches the sprout lines and 
counts them, gives the total length of the sprouts and the spheroid body area. Sprouting is 
defined as the total length of the sprouts normalized to the spheroid body area. 
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4.$Virus$production$and$infections$(I,$II,$III,$IV)$
The viruses used are listed in Table 3, and the details of the production and infections are 
described in the given references. Briefly, the wild type KSHV was produced in BCBL-1 
cells, and the recombinant KSHV (rKSHV.219) in the Vero cells by stimulating them with 
known chemical inducers of lytic reactivation (12-O-Tetradecanoyl-phorbol-13-acetate 
(TPA) for BCBL-1, and sodium buturate (NaB) combined with baculovirus expressing 
KSHV replication and transcription activator (RTA) for Vero). The concentrated virus in 
basal endothelial media supplemented with polybrene was used to spin-infect LECs at 
multiplicity of infection (MOI) 1, and the efficacy of infection was determined by LANA 
staining. The various overexpression and shRNA vectors used to produce lenti- and 
retroviruses are described in Tables 3 and 4. The VSV-pseudotyped lentiviruses were 
produced from HEK293FT cells transfected with the given vector and the packaging 
plasmids (pLP1, pLP2, pLP/VSVG), and concentrated by ultracentrifugation. The 
retroviruses were produced in Phoenix Ampho cells containing the retroviral packaging 
plasmids by transfecting only the desired construct. The lenti- and retroviruses were used 
as one time concentrated viral supernatant to spin-transduce HEK293A, HEK293-FlipIn, 
LEC, Bowes, and WM852 cells. The samples for further analysis were collected 48-72 h 
after transductions. 
 
Table 3. Viruses used in this study.   
virus description reference/source used in  
GFP-luc 
retrovirus 
retrovirus containing fusion eGFP-luciferase reporter Dr. Kaisa Lehti IV 
KSHV wild type KSHV produced from BCBL-1 cells Publication III III 
LANA 
lentivirus 
overexpression construct in pLenti6/V5/DEST lentiviral 
vector 
(Sarek et al., 
2006) 
III 
MT1-MMP 
retrovirus 
overexpression construct in  pMX-GFP retroviral vector (Ory et al., 1996) III 
rKSHV.219  recombinant KSHV containing the KSHV genome and 
expressing GFP under the cellular EF-1alpha promoter to 
detect all infected cells and RFP under the viral PAN 
promoter to detect cells in lytic infection phase  
 (Vieira and 
O'Hearn, 2004) 
III 
sh-CDK6 
lentivirus 
shRNA against human CDK6 in pDSL_hpUGIH backbone (Koopal et al., 
2007) 
II 
sh-CDK6_1 
lentivirus 
shRNA against human CDK6 in pLKO.1 vector backbone Biomedicum 
Functional 
Genomics Unit 
I 
sh-CDK6_2 
lentivirus 
shRNA against human CDK6 in pLKO.1 vector backbone Biomedicum 
Functional 
Genomics Unit 
I 
sh-scr 
lentivirus 
scrambled shRNA in pDSL_hpUGIH vector backbone (Koopal et al., 
2007) 
II 
sh-scr 
lentivirus 
scrambled shRNA in pLKO.1 vector backbone Biomedicum 
Functional 
Genomics Unit 
I 
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v-cyclin 
lentivirus 
overexpression construct in pBMN-IRES-GFP retroviral 
vector 
(Koopal et al., 
2007) 
III 
vFLIP 
lentivirus 
overexpression construct in pSIN-MCS lentiviral vector  (Lagos et al., 
2007) 
III 
vGPCR 
lentivirus 
overexpression construct in pSIN-MCS lentiviral vector (Lagos et al., 
2007) 
III 
$
5.$RNAi$(III)$For! RNA! interference! experiments,! cells! were! transfected! using! siRNAs! listed! in!Table! 4!with!Oligofectamine! (Invitrogen)! according! to!manufacturer’s! instructions.!Spheroids!were!prepared!one!day!post!siRNA!transfection.! 
$
$
Table!4.!shRNA/siRNA!constructs!used!in!this!study.! ! !
shRNA/siRNA! sequence/reference!no! source/reference! used!in!
CDK6!shRNA! 5′HGATCCGAGTAGTGCATCGCGATCTTTCAAGAGAAGATCGCGATGCACTACTCGGTTTTTTGAH3′!
(Koopal!et!al.,!2007)! II!
CDK6!shRNA_1! TRCN0000039747! Biomedicum!Functional!Genomics!Unit! I!
CDK6!shRNA_2! TRCN0000194893! Biomedicum!Functional!Genomics!Unit! I!
ctrl!siRNA!for!
vFLIP!
5'HAAGCGCGCUUUGUAGGAUUCGH3'!! (An!et!al.,!2003,!Guasparri!et!al.,!2004)! III!
ctrl!siRNA!for!
vGPCR!
5'HAGTACCGACATCCGACCAA!H3'! (Bottero!et!al.,!2009)! III!
MT1KMMP!
siRNA1!
5'HCAGCGATGAAGTCTTCACTTAH3'! Qiagen! III!
MT1KMMP!
siRNA2!
5'HTGGCGGGTGAGGAATAACCAAH3'! Qiagen! III!
! ! ! !
nonKtarget!
control!siRNA!!
ND! Qiagen! III!
nonKtarget!
control!siRNA!!
ND! Dharmacon! III!
PDGFRA!siRNA! siGENOME!SMARTpool! Dharmacon! III!
PDGFRB!siRNA! siGENOME!SMARTpool! Dharmacon! III!
scr!shRNA! 5′HATCCGTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTTGGAAAH3′!
(Koopal!et!al.,!2007)! II!
scr!shRNA! SHC005! Biomedicum!Functional!Genomics!Unit! I!
vFLIP!siRNA!1! 5'HAACGUGUUCAUACCUCAACCCH3'! (An!et!al.,!2003,!Guasparri!et!al.,!2004)! III!
vFLIP!siRNA!2! 5'HAAGUGGUAUUGUUCCUCCUAAH3'! (An!et!al.,!2003,!Guasparri!et!al.,!2004)! III!
vGPCR!siRNA1! 5'HGAACGTTGGAATACTCTCTH3'! (Bottero!et!al.,!2009)! III!
vGPCR!siRNA2! 5'HGGTACTGACATCCGCTGCAH3'! (Bottero!et!al.,!2009)! III!
!
$
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6.$Inhibitor$and$ligand$stimulation$assays$(I,$III,$IV)$
The inhibitors and ligands used are described in Table 5. Briefly, mouse lymphoma cells 
and PEL cells at a starting density of 2x105 cells/ml were incubated for 72 hours with 
DAPT (10 µM; Sigma) or PD0332991 (0.5-1 µM; Adooq Bioscience) or corresponding 
vehicle control (EtOH/DMSO). The number of live and dead cells were determined by 
trypan blue exclusion and counting with a TC10 Automated cell counter (Bio-Rad) at 0 h, 
24 h, 48 h and 72 h after adding the inhibitor. Cell pellets for analysis by real time 
quantitative PCR were collected at 24 h. For spheroid assays, the inhibitors were added 
into the medium after the spheroids were embedded into the fibrin gel and followed for 2–
4 days prior fixation or collection for RNA lysates. Human VEGF-A and VEGF-C were 
included in the medium 1 day before spheroid preparation, during spheroid formation, and 
for 2 days in 3D. In IV, the LEC-WM852 single- or co-cultures were treated with DAPT 
(10 µM; Sigma), AMD3100 (10 µM; Calbiochem), or their respective vehicle controls 
(DMSO/mock) for 48 hours prior the adhesion assay, during which the inhibitors were 
also kept on. 
 
Table 5. Inhibitors and ligands used in this study.   
Inhibitor 
/ligand 
description source/reference used in  
AMD3100 Inhibitor of CXCR4 ligand binding Calbiochem IV 
cytochalasin D inhibitor of actin polymerization Sigma III 
DAPT gamma-secretase inhibitor Sigma I, III, IV 
DLL4-Fc signal peptide and extracellular domain of human 
DLL4 fuced to human Fc fragment 
Prof. Kari Alitalo III 
GM6001 broad-spectrum matrix metalloproteinase inhibitor Calbiochem III 
nocodazole inhibitor of microtubule polymerization Sigma III 
PD0332991 CDK4/6 kinase inhibitor Adooq Bioscience I 
PDGF-AA ligand for PDGFR-α receptor R&D systems III 
PDGF-BB ligand for PDGFR-β receptor R&D systems III 
rTGFB-1 recombinant TGF-β R&D systems III 
SB431542 inhibitor of TGF-β superfamily type I activin receptor-
like kinase (ALK) receptors 
Sigma III 
SU16f PDGFR-β inhibitor Tocris Bioscience III 
TIMP-1 tissue inhibitor of metalloproteinases 1 R&D systems III 
TIMP-2 tissue inhibitor of metalloproteinases 2 R&D systems III 
VEGF-A vascular endothelial growth factor A R&D systems III, IV 
VEGF-C vascular endothelial growth factor C Prof. Kari Alitalo III, IV 
 
!
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7.!Immunofluorescence!(IF)!of!2D!and!3D!cultures!(II,!III,!IV) !
The 2D and 3D cultured cells were fixed with 4% paraformaldehyde for 15-60 min at 
room temperature, permeabilized with 0.1-0.3% Triton-X, and the 3D cultures were 
additionally treated with ice cold acetone-methanol for 1 min. Immunofluorescence was 
performed on fixed 2D or 3D cultures. The primary antibodies used are listed in Table 6. 
Stainings with omitted primary antibodies were used as negative controls. For the 
immunofluorescence detection, secondary antibodies labelled with fluorochromes Alexa 
Fluor 488, 594 and 647, Cy3, or Hoechst 33342 were used. The fluorescent images were 
aquired by using Zeiss epifluorescence microscopes, CellInsight automated 
epifluorescence microscope, or confocal imaging by Zeiss or Leica confocal imaging 
systems.  
 
8.!Immunofluorescence!or!immunohistochemistry!(IHC)!of!tissue!sections!(I,!II,!
IV)!
After dissection, mouse tissues and tumors were fixed with 4% paraformaldehyde for 24 h 
at +4°C, embedded in paraffin and cut into 5 µm sections. H&E stainings were performed 
according to standard protocols. Before primary antibody incubation, tissue sections were 
treated for antigen retrieval with 10 mM citrate buffer (pH 6.0) or 0.25% trypsin solution. 
The primary antibodies used are listed in Table 6. Omission of the primary antibody, or 
isotype and concentration matched primary antibodies served as negative controls. In 
immunohistochemical stainings, signal was detected and amplified using the tyramide 
signal amplification (TSA) biotin system kit (Perkin Elmer) according to the 
manufacturer’s instructions, and analyzed by Zeiss light microscopes. In fluorescent 
stainings, fluorochromes listed in section 7 were used for detection, and images were 
acquired by using Zeiss epifluorescence microscopes, or confocal imaging by Zeiss or 
Leica confocal imaging systems. The image analysis of the KS tissue stainings was done 
in a pipeline created in the Anduril framework (Ovaska et al., 2010). The permission to 
use KS tissue material from patients was given by the Helsinki University Central 
Hospital (HUCH) ethical committee (to Lauri Aaltonen, permission number: 
408/13/03/03/2009). 
 
9.$Fluorescence3activated$cell$sorting$(FACS)$(I)$
For FACS, 2x106 of freshly isolated splenic and thymic lymphocytes were incubated for 1 
h at +4°C with specific pre-conjugated antibodies listed in Table 6. After the surface 
marker labeling, lymphocytes were washed with 1% BSA in PBS and fixed with 0.01% 
paraformaldehyde for 15 min at +4°C, and washed twice. For Ki-67 stainings, the cells 
were permeabilized with 0.5% Tween 20 for 15 min before 1 h incubation at +4°C with 
the antibody. To determine the cell cycle profiles, lymphocytes were stained with 
propidium iodide (PI, Sigma) after fixation of the cells with 70% ethanol in -20°C. 
Labelled cells were acquired using a FACSAria II flow cytometer (BD Biosciences), and 
cell populations were analyzed by BD FACSDiVa Software v 6.1. 
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Table 6. Primary antibodies and stains used in this study.   
antibody 
against/ stain 
description source/reference used in 
Annexin V APC conjugated stain against apoptotic 
cells 
BD Pharmingen I: FACS 
α-SMA Cy3 conjugated mouse antibody, clone 
1A4 
Sigma III, IV: IF 
B220 rat antibody (RA3-6B2) Southern Biotech I: IHC 
CD3  rabbit antibody (A0452) Dako I: IHC 
CD3  PE-Cy7 conjugated primary antibody 
(145-2C11) 
BD Pharmingen I: FACS 
CD4  PE conjugated primary antibody, 
(H129.9)  
BD Pharmingen I: FACS 
CD8  FITC conjugated primary antibody (53-
5.8) 
BD Pharmingen I: FACS 
CD44 mouse antibody (sc-7297) Santa Cruz IV: IF 
CDK2 rabbit  antibody (sc-163) Santa Cruz I: IB, IP 
CDK4 rabbit antibody  (C22, sc-260) Santa Cruz II: IB 
CDK6  mouse antibody (#MS-451)  Thermo Scientific I, II: IB 
CDK6  rabbit antibody (C21, sc-177) Santa Cruz I, II: IB, IP 
Cyclin A rabbit antibody  (sc-596) Santa Cruz I: IB 
Cyclin D3  rabbit antibody (sc-182) Santa Cruz I, II. IB 
CXCR4 rabbit antibody R&D system IV: IF 
fibronectin rabbit antibody 
rabbit antibody 
Prof. Antti Vaheri 
Sigma 
III: IF 
IV: IHC 
flag M2  mouse antibody (F1804) Sigma I, II: IB, IP 
-tubulin  mouse antibody (GTU-88) Sigma I, II, III: IB 
GFP rabbit antibody Dr. Giuseppe Balistreri IV: IF 
Ki-67  PerCP-Cy5.5 conjugated antibody ( B56) BD Pharmingen I: FACS 
LANA rabbit antibody Prof. Bala Chandran III: IF 
LANA rat antibody ABI Biotechnologies III: IF 
LYVE-1 rabbit antibody against human LYVE-1 Prof. Pirjo Laakkonen III: IF 
LYVE-1 rabbit antibody against mouse LYVE-1 
(103-PA50) 
 Reliatec IV: IHC 
mouse IgG  (sc-2025) Santa Cruz III: IF 
MT1-MMP mouse antibody Chemicon III, IV: IF, 
IHC, IB 
N-cadherin rabbit antibody BD Pharmingen III: IF 
NICD1  (ab8925) Abcam I: IB 
NICD3 (sc-7424) Santa Cruz I: IB 
Notch3 (N5038) Sigma I: IF 
NPM mouse antibody (32-5200) Invitrogen I: IB 
NPM –
phospho-T199 
rabbit antibody (CST3541) Cell Signaling I: IB 
ORF59 mouse antibody Prof. Bala Chandran III: IF 
p65 rabbit antibody (sc-372) Santa Cruz II: IB, IF 
p65 phospho-
Ser536 
rabbit antibody (CST3033) 
 
Cell Signaling II: IB, IF 
PDGFR-α  mouse antibody  Santa Cruz III: IB, IF 
PDGFR-β mouse antibody Santa Cruz III: IB, IF 
PECAM-1 mouse antibody Dako III, IV: IF 
 rat antibody BD Pharmingen IV: IHC 
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Phalloidin stain for actin cytoskeleton, Alexa488 
conjugated 
Invitrogen IV: IF 
podoplanin rabbit antibody (Breiteneder-Geleff et 
al., 1999) 
III: IF 
Prox-1 goat antibody (AF2727) R&D Systems IV: IF 
rabbit IgG  (sc-2027) Santa Cruz III: IF 
rat IgG  (sc-2026) Santa Cruz III: IF 
SP1  (PEP2, sc-59) Santa Cruz II: IB 
transgelin   Abcam III: IF 
v-cyclin rabbit antibody (Sarek et al., 2006) I, II: IB, IP 
VE-cadherin mouse antibody (555661) 
 
BD Pharmingen III, IV: IF 
VE-cadherin goat antibody (AF357) R&D Systems IV: IF 
VEGFR3  mouse antibody (clone 9D9) (Jussila et al., 1998) III: IF 
vimentin  mouse antibody V9; Dako III: IF 
ZO-1 rabbit antibody Zymed III: IF !
10.$ Subcellular$ fractionation,$ immunoprecipitations$ (IP),$ in# vitro# kinase$
reaction,$and$immunoblotting$(IB)$(I,$II,$III)$
For immunoprecipitations, and their whole cell lysate controls, cells were lysed in an ELB 
lysis buffer (50 mM Hepes (pH 7.4), 150 mM NaCl; 50 mM HEPES, pH 7.4; 0.1% Igepal; 
5 mM EDTA). Alternatively, the total cell lysates were prepared in Urea-Tris lysis buffer 
(UTB) (9 M Urea, 75 mM Tris-HCl, pH 7.5, 0.15 M 2-mercaptoethanol) or NET buffer 
(150 mM NaCl, 50 mM EDTA, 100 mM Triton-X100), and subcellular fractionations 
were done using series of lysis buffers as earlier described (Sarek et al., 2006). All lysis 
buffers were supplemented with complete proteinase inhibitor cocktail (Thermo 
Scientific), and phosphatase inhibitory cocktail when appropriate (PhosphoSTOP, Roche), 
and the lysates were homogenized by passing the cell lysate through a 23-gauge needle or 
sonication, and cleared by centrifugation. For immunodepletions or immunoprecipitations 
(IP) 300-1000 µg of protein were used per sample and incubated with antibodies listed in 
Table 6.  In vitro kinase reaction was performed after IP by using GST-Rb and Histone H1 
as substrates. Immunoprecipitated and total proteins (15-75 µg) were subjected to SDS-
PAGE and transferred to nitrocellulose membranes. For immunoblotting (IB), membranes 
were probed with antibodies described in Table 6. 
 
11.$Real$time$quantitative$PCR$(qRT3PCR)$(I,$III,$IV)$
Total RNA was extracted using the RNeasy mini kit (Qiagen) or the NucleoSpin RNA II 
kit (Macherey Nagel). Transcript levels were measured by qRT-PCR using Taqman Gene 
Expression Assays (Applied Biosystems) with the FAM-labeled primers, or unlabeled 
primers using the SYBR Green PCR mix (Fermentas) in the StepOnePlus Real Time PCR 
system (Applied Biosystems), in the Lightcycler 480 (Roche), or! in!the!Biorad_CFX384!RealHTime!detection!system!(Biorad). The primer sequences used are listed in Table 7. 
The data were normalized to expression of the cellular housekeeping genes, GAPDH or 
actin (ACT). 
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Table 7. Primers used in this study.   
Primer 
against 
sequence/reference source used in 
ACT TCACCCACACTGTGCCATCTACGA, 
CAGCGGAACCGCTCATTGCCAATGG 
Oligomer III, IV 
CD31 AACAGTGTTGACATGAAGAGCC, 
TGTAAAACAGCACGTCATCCTT 
Oligomer IV 
CD34 TGGGCATCACTGGCTATTTC, 
CCACGTGTTGTCTTGCTGAA 
Oligomer IV 
CDH2 Hs00169953_m1 Applied Biosystems III 
CDK6 CCAGATGGCTCTAACCTCAGT, 
AACTTCCACGAAAAAGAGGCTT 
Oligomer I 
CNN1 Hs00154543_m1 Applied Biosystems III 
COL1A1 Hs00164004_m1 Applied Biosystems III 
CXCL12 TGCCAGAGCCAACGTCAA, 
CAGCCGGCCGGCTAC 
Oligomer IV 
CXCR4 Hs00976734_m1 Applied Biosystems III 
 GCCAACGTCAGTGAGGCAGA, 
GCCAACCATGATGTGCTGAAAC 
Oligomer IV 
DLL4 CTGGAGCTCAGCGAGTGTGAC,!CCTGGTCCTTACAGCTGCCTC Oligomer IV 
ETS2 Hs00232009_m1 Applied Biosystems III 
FLT4 Hs01047679_m1 Applied Biosystems III 
 GACAGCTACAAATACGAGCATCTG, 
CTGTCTTGCAGTCGAGCAGAA 
Oligomer IV 
FOXF1 Hs00230962_m1 Applied Biosystems III 
FOXF2 Hs00230963_m1 Applied Biosystems III 
Gapdh Mm03302249_g1 Applied Biosystems I 
 TCAACGACCCCTTCATTGAC, 
ATGCAGGGATGATGTTCTGG 
Oligomer I 
GAPDH Hs03929097_m1 Applied Biosystems I, III, IV 
 TCACCACCATGGAGAAGGCT, 
GCCATCCACAGTCTTCTGGG 
Oligomer I, IV 
GFP AAGCTGACCCTGAAGTTCATCTGC, 
CTTGTAGTTGCCGTCGTCCTTGAA 
Oligomer IV 
Hes1 Mm01342805_m1 Applied Biosystems I 
HES1 Hs00172878_m1 Applied Biosystems I, III 
 TCAACACGACACCGGATAAA, 
TCAGCTGGCTCAGACTTTCA 
Oligomer IV 
Hey1 Mm00468865_m1 Applied Biosystems I 
HEY1 Hs00232618_m1 Applied Biosystems I, III 
 GTTCGGCTCTAGGTTCCATGT, 
CGTCGGCGCTTCTCAATTATTC 
Oligomer IV 
HEY2 TTGAGAAGACTTGTGCCAACTG, 
GTGCGTCAAAGTAGCCTTTACC 
Oligomer IV 
JAG1 TGCCAAGTGCCAGGAAGT, 
GCCCCATCTGGTATCACACT 
Oligomer IV 
K8.1 AAAGCGTCCAGGCCACCACAGA, 
TTCACTGCTGGTATCTGGAACG 
Oligomer III 
LANA  CGGAGCTAAAGAGTCTGGTG, 
GCAGTCTCCAGAGTCTTCTC 
Oligomer III 
MMP14 Hs01037009_m1 Applied Biosystems III 
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 GCAGAAGTTTTACGGCTTGCAA, 
CCTTCGAACATTGGCCTTGAT 
Oligomer IV 
MMP15 Hs00233997_m1 Applied Biosystems III 
MMP16 Hs00234676_m1 Applied Biosystems III 
Notch1  CCGTGTAAGAATGCTGGAACG, 
AGCGACAGATGTATGAAGACTCA 
Oligomer I 
NOTCH1 GAGGCGTGGCAGACTATCATGC, 
CTTGTACTCCGTCAGCGTGA 
Oligomer I, IV 
NOTCH2 CCTGGGCTATACTGGGAGCTACTG, 
ACACCCTGATAGCCTGGGACAC 
Oligomer IV 
Notch3  Mm00435270_m1 Applied Biosystems I 
NOTCH3 QT00003374 Qiagen I, IV 
NOTCH4 AATCCCACTGCCTCCAGACT, 
TTGTGGCAAAGGGAAGAGAC 
Oligomer IV 
NRARP Hs01104102_m1 Applied Biosystems III 
ORF25  GTCCACCCCTTCTTTGATTTTT, 
TTTCCCGAGTTGACCCAGTAGG 
Oligomer III 
ORF50  CACAAAAATGGCGCAAGATGA, 
TGGTAGAGTTGGGCCTTCAGTT 
Oligomer III 
PAI1  CAGGAAGCCCCTAGAGAACC, 
ATGCGGGCTGAGACTATG AC 
Oligomer III 
PDGFRA Hs00183486_m1 Applied Biosystems III 
PDGFRB Hs01019589_m1 Applied Biosystems III 
PROX1 Hs00896294_m1 Applied Biosystems III 
 TGTTCACCAGCACACCCGCC, 
TCCTTCCTGCATTGCACTTCCCG 
Oligomer IV 
pSIN  GTTTGCTACTGGAAAAAGAGGAAAGAG, 
AGGGCTGCTACGCTGCC 
Oligomer III 
S100A4 Hs00243202_m1 Applied Biosystems III 
SNAI1  AATCGGAAGCCTAACTACAGCG, 
GTCCCAGATGAGCATTGGCA 
Oligomer III 
SNAI2 Hs00950344_m1 Applied Biosystems III 
SPP1 Hs00959010_m1 Applied Biosystems III 
TAGLN Hs00162558_m1 Applied Biosystems III 
v-cyclin CGGACGTCACTTCCTTCTTG, 
CGCAGATCAAAGTCCGAAAC 
Oligomer I 
VEGFC GCAGTTACGGTCTGTGTCCA, 
TGTAATTGGTGGGGCAGGTC 
Oligomer IV 
vFLIP GCGGGCACAATGAGTTATTT, 
GGCGATAGTGTTGGGAGTGT 
Oligomer III 
vGPCR  TGGCCCAAACGGAGGATCCTAG, 
AGTTTCATTCCAGGATTCATCATC 
Oligomer III 
vIL-6 AAAACACGCACCGCTTGACCTG, 
TTCACTGCTGGTATCTGGAACG 
Oligomer III 
VIM Hs00958816_m1 Applied Biosystems III 
vIRF-2  CGGAATGGCTCACGGACTTTAT, 
AGACATCCTTCACATCCCTTGT 
Oligomer III 
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ZEB1 GATGATGAATGCGAGTCAGATGC, 
ACAGCAGTGTCTTGTTGTTGTAG 
Oligomer III 
 
12.$Global$gene$expression$analyses$(III,$IV)$
Total RNA was extracted using the RNeasy mini kit (Qiagen) or with Trizol isolation 
protocol (Sigma) supplemented with acid phenol-chloroform precipitation step. The RNA 
integrity was analyzed by Bioanalyzer (Agilent). In III, Affymetrix Hg-U133 plus 2.0 
microarrays were used according to manufacturer’s procedures, and the genome 
annotations were taken from the Bioconductor’s repository package ‘hgu133plus2.db’. In 
IV, the RNA sequencing was done by using the standard protocols and the Illumina 
NextSeq500 sequencer, the reads were aligned to HS GRCh38.76 reference genome, and 
Bioconductor’s DESeq2 package was used to determine the differentially expressed genes 
from the count data. In both analyses, p-values less than 0.05 were considered significant.  
 
13.$Statistical$Analysis$(I,$II,$III,$IV)$
For statistical analysis of the qRT-PCR data logarithmic values were converted to ddCt 
values (log2 scale values) and p-values were calculated with a one-tailed unpaired 
Student's t-test. The p-values for FACS data were calculated directly from the data 
normalized to the appropriate control.  
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RESULTS$AND$DISCUSSION$
1.$KSHV$V3CYCLIN$EXPRESSION$LEADS$TO$DIFFERENTIATION$DEFECTS$IN$
LYMPHOCYTE$COMPARTMENT$IN#VIVO$(I,II)$
$
1.1$v3cyclin$expression$under$the$E 3promoter/enhancer$leads$to$T3cell$$
lymphoma$dependent$on$Cdk6$ 
To study viral cyclin mediated oncogenesis mechanisms in vivo (I, II), a previously 
described model in which v-cyclin expression was targeted to lymphocytes using the Eµ-
promoter/enhancer in a mixed CBA/C57BL6 background was utilized. This resulted in the 
development of B- and T-cell lymphomas in 17% of the mice, which was accelerated by 
breeding the mice with the p53 null background (Verschuren et al., 2004a, Verschuren et 
al., 2002). However, since wild type p53 is usually retained in KSHV associated 
lymphomas (Sarek et al., 2007), better models for studying the v-cyclin induced 
lymphomagenesis were needed. Our results showed that the disease progression and 
survival of the mice was dependent on the mouse background, as breeding these mice into 
an ICR (CD1) outbred stock and the inbred C57BL6 strain had different consequences. In 
the ICR strain, v-cyclin expression led to poor survival, as less than 5% of the mice were 
alive after a follow-up period of 300 days, even though p53 and p19ARF were found not 
to be mutated in the mouse background (Fig. 1A in I). Backcrossing the mice into the 
C57BL6 strain resulted in reversion of the survival rate to similar as found in the original 
mixed background (Fig. S1A in I). This might be reflecting the intrinsic resistance to 
tumor formation described earlier in the C57BL6 mouse strain (Meuwissen and Berns, 
2005), or the two-fold higher expression levels of v-cyclin seen in the ICR background 
(Fig. S1B in I).  
 
The low survival rates of the ICR-v-cyclin mice were due to lymphomas mainly in the 
thymus and spleen, and pancarditis manifested as lymphocyte masses in the heart causing 
destruction of the heart muscle and failure of the hemodynamics (Fig. 1B and 1F in I). The 
lymphomas formed in the ICR-v-cyclin mice were of T-cell origin, although the 
expression of v-cyclin was hundreds of folds higher in the B-cells than T-cells (Fig. 1C in 
I). Since v-cyclin is known to induce DNA damage and apoptosis in cell culture models 
when overexpressed (Koopal et al., 2007, Ojala et al., 1999, Ojala et al., 2000, Verschuren 
et al., 2002), it is possible that tight regulation of the v-cyclin levels is needed for the 
tumor formation. Another explanation is that the pathways v-cyclin is affecting are 
important for the T-cell but not B-cell development, and thus their deregulation would 
lead primarily to formation of a T-cell type malignancy. The most well-characterized 
cellular partner of v-cyclin, CDK6, is known to be important for T-cell differentiation, and 
to be a driver of the T-cell lymphomagenesis (Chilosi et al., 1998, Grossel and Hinds, 
2006b, Grossel and Hinds, 2006a, Hu et al., 2011, Sawai et al., 2012). Our results support 
the role of Cdk6 on participating in the v-cyclin induced T-cell lymphomas. Cdk6 was the 
predominant kinase in phosphorylating the tested in vitro substrates, GST-Rb and histone 
H1, together with v-cyclin when the freshly isolated mouse splenocytes were analyzed 
(Fig. 2D in I). Moreover, v-cyclin induced lymphomas were sensitive for the CDK4/6 
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kinase inhibitor, PD0332991, since the inhibitor treatment led to a cell cycle arrest and 
induced cell death in the lymphoma cell lines examined (Fig. 3A-B in I). To test whether 
the active CDK6-(v)-cyclin complexes were needed for the cell survival in the context of 
whole virus infection, the PD0332991 inhibitor was tested on patient derived, naturally 
KSHV infected PEL cells. CDK6 inhibition led to significant cell death in the BCBL-1 
PEL cell line (Fig. 3D in I). These results thus suggest that the use of CDK4/6 inhibitors 
could be beneficial in KSHV associated malignancies and perhaps in cancers where the D 
type cyclin or interphase CDK (CDK4/6) expression is upregulated. In recent years, 
interphase CDKs have proven to be promising drug targets, as they are not frequently 
mutated in cancer but most cancer cells need their function, whereas they are not essential 
for the survival of normal cells (Musgrove et al., 2011). CDK4/6 kinase inhibitors have 
proven relatively safe in clinical trials, and are tested as therapeutics in many cancer types, 
including estrogen receptor (ER)-positive breast cancer and chronic lymphocytic leukemia 
(Brower, 2014). Hence, their trial in the KSHV associated malignancies, and especially 
PEL, would be justifiable as well. 
 
1.2$T3cell$development$is$distorted$by$v3cyclin$expression$
When the v-cyclin induced lymphomas were further analyzed by FACS and antibodies 
against CD4/CD8 T-cell subpopulations, most of the lymphomas exhibited a CD4-CD8 
double negative phenotype (Fig. 1D in I). This suggests that a v-cyclin induced oncogenic 
event took place at the early phase of the T-lymphocyte maturation and might additionally 
hinder the T-lymphocyte development, given that differentiation and tumorigenesis are 
closely linked processes (Aifantis et al., 2008). To detect possible defects in the 
maturation of the lymphocytes, the thymi and spleens of the Eµ-v-cyclin mice were 
analyzed before the onset of the lymphomas. The size and cellularity of these lymphoid 
organs were significantly diminished when compared to the littermate control animals 
(Fig. 4A-B and S4A-B in I), indicating that v-cyclin expression was affecting the survival 
of some or all of the lymphocyte subtypes. When the thymocytes and splenocytes were 
subjected to analyses on proliferation, apoptosis, and cell cycle by FACS, the results 
indicated that the turnover of the v-cyclin expressing cells had increased (Fig. 4C-E in I). 
This implies that the decreased lymphoid organ size did not result from increased 
apoptosis or decrease in proliferation. Supporting the role of v-cyclin in disturbing T-cell 
differentiation, the v-cyclin expressing animals showed diminished CD3 expression over 
B220 expression when the spleens were analyzed by IHC and FACS (Fig. S4C-D), 
indicating that the T-lymphocytes did not reach the secondary lymphoid organs. When the 
T-cell maturation in the thymus was analyzed by FACS, the number of CD4-CD8 double 
negative and double positive, as well CD8 single positive cells had decreased. Peculiarly, 
the number of CD4 single positive cells had increased (Fig. 5C in I), and these cells were 
mostly pan-T-cell marker CD3 negative (Fig. 5F in I). When compared to thymocytes of 
the littermates, both the thymocytes and lymphoma cell lines isolated from the Eµ-v-
cyclin mice showed a ten-fold increased expression of the plasma cell marker CD138 (Fig. 
1E and 5G in I), which is also expressed by the PEL cells (Carbone et al., 2000, Gaidano 
et al., 1997). Taken together, v-cyclin expression leads not only to a block in the 
differentiation of the T-lymphocytes but also induces cell populations normally not 
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present in the thymi.  As PEL cells exhibit an intermediate plasma cell phenotype (Klein 
et al., 2003), and PELs expressing T-cell markers have been characterized (Goto et al., 
2013, Nepka et al., 2012, Said et al., 1999), it is possible that v-cyclin accounts for some 
of the differentiation alterations seen in this KSHV induced malignancy. In general, this is 
another example of how an oncogene expression can lead to differentiation defects, which 
then further leads to tumorigenesis. 
 
1.3$v3cyclin$induces$the$proinflammatory$NF3 B$pathway$via$Cdk6$$
dependent$phosphorylation 
Since about half of the lethally diseased Eµ-v-cyclin mice exhibited signs of pancarditis, 
we hypothesized that v-cyclin could affect pathways related to inflammation. The NF-κB 
pathway has been heavily linked to (auto)immunity and cancer (Hoesel and Schmid, 2013, 
Sun et al., 2013), as well as to KSHV pathogenesis (de Oliveira et al., 2010). As all the 
currently known v-cyclin functions are mediated by CDK6 dependent phosphorylations, 
we wanted to decipher whether the v-cyclin-CDK6 complex could phosphorylate the NF-
κB effectors. By using an unbiased approach based on ion exchange chromatography after 
IL-1 stimulation, it had been previously shown that the NF-κB effector p65 could be 
phosphorylated at S536 (pS536-p65) by five distinct kinases (Buss et al., 2004). These 
kinases included IKKα, IKKβ, IKKε, TRAF family member-associated-binding kinase 1 
(TBK1), and an unknown kinase (Buss et al., 2004). In our study, further fractionation and 
mass spectrometry analysis revealed that the identity of the unknown kinase was CDK6 
(Fig. 1 in II). Furthermore, pS536-p65 co-immunoprecipitated with CDK6, and in vitro 
kinase assay showed that recombinant CDK6 together with v-cyclin could phosphorylate 
the same site on p65 (Fig. 2 in II). Inhibition of CDK6 by silencing or chemical inhibitors 
in cell models led to attenuation in TNF/IL-1 stimulated p65 S536 phosphorylation, a 
decrease in NF-κB luciferase reporter signal, and a decrease in the expression of NF-κB 
target genes (Fig. 3A-C and 4 in II). Moreover, CDK6 silencing in PEL cells led to 
downregulation of p65 phosphorylation at S536 in the nucleus (Fig. 3D-E in II). Hence, v-
cyclin-CDK6 complex in virus context is activating and fine-tuning the NF-κB pathway, 
and thus most probably regulates the inflammatory response seen in KS/PEL. This is 
particularly intriguing given that the PEL cells have been shown to be dependent on 
constitutive NF-κB activity, vFLIP has been shown to induce the pathway via IKK 
(Guasparri et al., 2004, Keller et al., 2000), and there has been reports showing that other 
KSHV encoded proteins can modify the NF-κB pathway as well (de Oliveira et al., 2010). 
Taken together, these results reveal that KSHV regulates the NF-κB pathway by several 
different mechanisms. This highlights the importance of the pathway not only for KSHV 
immune evasion but also for the KSHV mediated induction of malignancies through NF-
κB pro-tumorigenic effects.  
 
In vivo, pS536-p65 was induced in the v-cyclin expressing pre-tumorigenic lymphatic 
organs of the Eµ-v-cyclin mice and even more pronouncedly in the thymic lymphomas 
when compared to the littermate controls (Fig. 6A-B in II). As this correlated with the 
CDK6 levels of the given organs, and since CDK6 gave the highest kinase activity with v-
cyclin in an in vitro kinase assay performed using the isolated Eµ-v-cyclin splenocytes 
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(Fig. 2D in I), it is probable that the phosphorylation of p65 on S536 is mediated by 
CDK6. CDK6 can, however, phosphorylate p65 and other targets also with the cellular 
cyclin D, and cyclin D3 was significantly induced in the v-cyclin expressing lymphoid 
organs and lymphomas (Fig. 6A in II and Fig. 6E in I). Thus, even though the in vitro data 
suggests that v-cyclin-CDK6 complex is inducing p65 phosphorylation slightly more 
potently than CDK6-cyclin D complexes (Fig. 2A in II), it cannot be ruled out that part of 
the pS536-p65 seen in the lymphoid organs and thymic lymphomas of the Eµ-v-cyclin 
mice would be the consequence of increased activation of the CDK6-cyclin D complex. In 
either case, as the isolated lymphoma cell lines from the Eµ-v-cyclin mice treated with 
CDK4/6 kinase inhibitors showed compromised survival, it is tempting to postulate that 
part of the survival mechanism in the Eµ-v-cyclin lymphomas is mediated by the CDK6 
dependent NF-κB activation. Moreover, if the increased phosphorylation of p65 leads to 
similar cytokine response in vivo as in the cell culture models, it is plausible to surmise 
that activated NF-κB could mediate the lethal pancarditis seen in the Eµ-v-cyclin mice. 
$
1.4$Notch$pathway$activation$accounts$for$T3cell$defects$in#vivo#
The Notch pathway has been shown to be one of the most important regulators of T-cell 
fate (Lefort et al., 2006), and NOTCH1 is the most often mutated gene in the human T-cell 
acute lymphoblastic leukemia T-ALL (Weng et al., 2004). As it has been shown that 
Notch signaling supports the survival of the KSHV lymphoma cells (Lan et al., 2009), we 
hypothesized that the Notch signaling pathway might be involved in causing the observed 
defects in the T-cell development as well as T-cell lymphoma seen in the Eµ-cyclin mice. 
To this end, the expression levels of Notch receptors and their targets from the pre-
tumorigenic tissues and lymphomas isolated from the Eµ-cyclin mice were analyzed. 
From the Notch receptors, Notch1 and Notch3 were expressed in the mouse thymocytes. 
Notch3 and its intracellular activated domain NICD3 were upregulated both in the v-
cyclin expressing thymocytes and thymic lymphomas when compared to the littermate 
controls, whereas Notch1 expression was solely upregulated in the lymphoma phase (Fig. 
6A-C in I). Appropriately, the Notch downstream targets Hes1 and Hey1 were upregulated 
already in the pre-tumorigenic phase, and Hes1 expression had further increased in the 
thymic lymphomas (Fig. 6D in I), whereas Hey2 and Hes5 were not expressed at the 
mouse thymocytes. These results suggest that the increased amounts of activated Notch3 
could cause the defects in the T-cell development and participate in the initiation of the 
lymphomas, whereas Notch1 upregulation seems to be secondary to the lymphomagenesis 
but could still further increase the downstream target expression and be crucial for the 
lymphoma survival. Further corroborating evidence on the functional significance of the 
activated Notch signaling in the Eµ-cyclin lymphomas came from the assays using the 
gamma secretase inhibitor DAPT, which prevents the cleavage of the Notch receptor to an 
active intracellular domain and leads to abortion of the Notch target gene expression. 
Treating the isolated Eµ-cyclin lymphoma cells with DAPT led to cell cycle arrest and 
increased cell death, suggesting that constitutively active Notch signaling was required for 
the survival of the Eµ-cyclin lymphoma cells (Fig. 7C in I). Earlier studies have shown 
that PEL cells in culture and in xenograft models are dependent on activated Notch (Lan et 
al., 2009) and suggested that treating KSHV associated malignancies with gamma 
  
!
RESULTS(AND(DISCUSSION(
!
! !
59 
secretase inhibitors might be beneficial. Our results further show that v-cyclin can 
participate in the Notch activation in an appropriate context and, thus, support the use of 
these inhibitors to treat these malignancies.  
 
To study if the v-cyclin induced Notch activation was dependent on CDK6, its expression 
was silenced in a human cell culture model. As v-cyclin expression in cell culture can lead 
to DNA damage, cellular senescence, or apoptosis, we chose to study the role of CDK6 in 
a HEK293 cell line, which has NOTCH3 expression already without v-cyclin. We 
silenced CDK6 expression by lentivirus-mediated shRNA, which led to downregulation of 
NOTCH3 and HES1 in this model (Fig. 6F in I), implying that the Notch activation can 
indeed be dependent on CDK6. In conclusion, the results show that cyclin-CDK can have 
a role in the initiation of Notch-dependent lymphomagenesis, possibly through 
interference with the development of the lymphocytes. It has been previously shown that 
Notch increases cell survival through induction of cyclin D3 expression in T-cell 
malignancies (Joshi et al., 2009, Sicinska et al., 2003, Choi et al., 2012). In the Eµ-cyclin 
mice, the cyclin D3 expression is induced, and we show that a cyclin can act as an 
upstream regulator of Notch. These findings argue against cyclins being solely 
downstream effectors of cell proliferation and raise a question whether cellular cyclins can 
also function upstream of Notch and possibly other pathways. Indeed, there has been a 
report showing that cyclin D1 can act as an upstream transcriptional regulator of Notch1 
in a developing mouse eye (Bienvenu et al., 2010). Nevertheless, the mechanism leading 
to Notch activation seems to be different from our model, since the Notch1 expression in 
mouse retina did not require CDK6 function, but cyclin D1 expression was found to 
directly lead to RBP-Jκ binding at the Notch1 promoter (Bienvenu et al., 2010).  
 
$
2.$TRANSDIFFERENTIATION$OF$PRIMARY$LYMPHATIC$ENDOTHELIAL$
CELLS$CONTRIBUTES$TO$CELLULAR$HETEROGENEITY$IN$KAPOSI’S$
SARCOMA$(III)$
$
2.1$Kaposi’s$sarcoma$exhibits$cellular$heterogeneity$
It has been known that Kaposi’s sarcoma (KS) tumors express a variety of different 
cellular lineage markers, including markers of blood and lymphatic endothelial cells, 
fibroblasts, smooth muscle cells, and several immune system cells (Kaaya et al., 1995, 
Sturzl et al., 1995, Weich et al., 1991). As the tumors contain multiple cell types, we 
wanted to test whether the cells expressing the mesenchymal/fibroblast markers were 
KSHV infected tumor cells. We double stained human KS tumor sections for KSHV latent 
antigen LANA and several of the mesenchymal lineage markers. The majority of the KS 
spindle cells were found to co-express LANA and vimentin as well as LANA and 
PDGFR-α, while a subgroup of the spindle cells simultaneously expressed LANA and α-
SMA (Fig. 1, S1 and Table S1 in III). These results demonstrated that the KS tumor cells 
were heterogeneous in their lineage marker expression, and even though they are thought 
to be of endothelial origin and express several endothelial lineage markers, they also 
express markers of smooth muscle cells and fibroblasts. The possible explanations for the 
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heterogeneous lineage marker expression are that 1) several different cell types can be 
infected and transformed, 2) a common progenitor cell is transformed, or 3) KSHV causes 
transdifferentiation of the originally infected cell. It does not seem likely that a 
simultaneous transformation process would occur in multiple cell types and finally result 
in similar morphology of the tumor cells. In turn, it has been shown that especially human 
mesenchymal stem cells are not easily infected in vitro, suggesting that the progenitor 
cells might not be the major target cells of KSHV (unpublished observation by E. 
Kaivanto and ref. (Yoo et al., 2014)). Thus, the most probable explanation for the different 
lineage marker expression is that endothelial cells can transdifferentiate towards 
mesenchymal fate or vice versa. As EndMT is a morphogenic process used in 
development, the endothelial cells are infected with KSHV rather easily, and the 
prevailing view of the KSHV origin supports endothelial cells (Cancian et al., 2013), we 
hypothesized that EndMT was contributing to the cellular heterogeneity seen in the KS 
tumors. 
 
2.2$3D$culture$of$KSHV$infected$LECs$leads$to$reprogramming$towards$$
mesenchymal$cell$fate$
Upon KSHV infection, endothelial cells adopt spindle morphology and exhibit a vast array 
of gene expression changes, reviewed in (Cancian et al., 2013). In BECs, it has been 
shown that KSHV infection can lead to expression of LEC markers, whereas KSHV 
infected LECs (K-LEC) acquire BEC markers (Carroll et al., 2004, Hong et al., 2004, 
Wang et al., 2004). This suggests that KSHV infected endothelial cells are able to undergo 
cellular transdifferentiation. However, fibroblast/smooth muscle cell marker expression in 
spindle cells was not explained by these findings. To study if this was due to cell culture 
conditions not permissive for transdifferentiation beyond the endothelial cell fate, we 
cultured K-LECs in 3D conditions, better mimicking the cellular milieu in vivo. As KS 
tumors contain a myriad of leaky vessels and thus grow in environment rich in fibrin, we 
chose to use cross-linked fibrin matrix and adapted an assay developed for angiogenesis 
studies (Korff and Augustin, 1998), where preformed EC clusters called spheroids are 
embedded into fibrin matrix. Interestingly, embedding the K-LEC spheroids into the fibrin 
matrix resulted in frequent outgrowth of the cells (sprouting) from the spheroid body, 
whereas uninfected LEC spheroids did not sprout (Fig. 2A in III). These sprouts did not 
represent lymphangiogenesis as they had lost expression of endothelial cell markers, but 
instead gained expression of fibroblast and smooth muscle cell markers such as α-SMA, 
vimentin, N-cadherin, transgelin, and fibronectin (Fig. 2B-C and S2). Furthermore, known 
EMT/EndMT effectors Snail and PDGFR-β were upregulated in the K-LEC spheroids 
(Fig. 2C and S3B in III). Thus, it seemed that a portion of the K-LECs in contact with the 
3D matrix had undergone EndMT. This finding explains the high cellular heterogeneity 
seen in KS tumors and supports the role of LECs as a source of KS spindle cells. As 
mesenchymal cells are generally more motile than endothelial cells, EndMT might be a 
frequent event needed for the spread of the endothelial cell derived tumor cells in KS. In 
other cancer types where endothelial cells are not directly affected by cancer initiating 
mutations, its role is more obscure. However, reports from Kalluri and colleagues have 
described that EndMT can serve as a major source of CAFs in melanoma and pancreatic 
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cancer (Zeisberg et al., 2007a), and thus facilitate the tumor progression also in other 
contexts beyond KS. 
 
2.3$Angiogenesis$and$EndMT$are$opposing$events$which$are$balanced$in$the$
tumors$
In addition to the peculiar KS spindle cells, the heterogeneity of the KS tumors involves 
angiogenesis and leaky blood vessels, both phenotypes resulting from increased VEGF 
signaling (Koch et al., 2011). Furthermore, it has been shown that VEGF is secreted by the 
KS tumor cells (Cornali et al., 1996, Masood et al., 1997, Nakamura et al., 1997), and that 
KSHV lytic gene vGPCR expression can lead to increased expression of VEGF and its 
receptor VEGFR-2 (Jham and Montaner, 2010, Bais et al., 2003, Sodhi et al., 2004a, 
Sodhi et al., 2000).  Additionally, other factors, including Angiopoietin-like 4 
(ANGPTL4), have also been shown to participate in the increased angiogenesis and 
vascular permeability induced by KSHV vGPCR (Ma et al., 2010). To study the effect of 
high concentration of angiogenic factors on the transdifferentiation phenotype, the 3D K-
LEC cultures were stimulated with VEGF or VEGF-C. Adding either of the growth 
factors led to increased sprouting from the spheroid body compared to the non-stimulated 
K-LEC spheroid. However, these sprouts expressed markers of (lymph)angiogenesis, 
namely PECAM, and did not express α-SMA or fibronectin, which were in turn expressed 
by the non-stimulated spheroid sprouts (Fig. 3G in III). Thus, the endothelial growth 
factors at high levels can override the EndMT phenotype and lead to increased angiogenic 
sprouting. This fits to the KS context where both phenotypes are present, probably 
representing the different ends of the VEGF gradients in the microenvironment, or 
intrinsic differences in the susceptibility of the tumor cells to the angiogenic factors, 
bearing in mind that the VEGF receptors and other endothelial markers can also be 
downregulated by KSHV (Carroll et al., 2004, Hong et al., 2004, Wang et al., 2004, 
Mansouri et al., 2006, Qian et al., 2008) and (Fig. S2 in III). Furthermore, hypoxic 
conditions seen in the KS tumor microenvironment can further complex the cell fate 
determination. Hypoxia has been shown to lead to increased angiogenesis through HIF-
1α-VEGF axis (Baeriswyl and Christofori, 2009), but it can also serve as an initiator of 
EMT (Higgins et al., 2007, Jiang et al., 2011) and is a physiological stimulus of KSHV 
reactivation (Davis et al., 2001). Reactivation can lead to increased viral loads and 
expression of hundreds of viral genes, which can in turn affect the EndMT process as well 
as angiogenesis. Indeed, we detected that inside the spheroid body, which represents the 
more hypoxic environment, there was an increase in the expression of viral lytic genes 
(Fig. 7B-C). Generation of new virus particles could possibly facilitate the spread of the 
virus and balance the switch between angiogenesis and EndMT by currently unknown 
mechanisms.  
 
$
$
$
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2.4$Notch$pathway$activity$is$required$for$EndMT$by$KSHV$
Mechanisms leading to EndMT in the cancer context are not well understood, but it is 
known that the major pathways driving EndMT in development are TGF-β and Notch 
pathways (Garside et al., 2013). We tested the role of these pathways in KSHV induced 
EndMT by using different chemical inhibitors. The Notch pathway inhibition by DAPT or 
inhibitor of soluble Dll4/Notch signaling (Dll4-Fc) led to decreased sprouting of the K-
LEC spheroids and downregulated expression of mesenchymal markers in qRT-PCR (Fig. 
3E-F and S3D-E in III).  On the other hand, an inhibitor of the TGF-β downstream kinases 
(SB431542) or a TGF-β blocking antibody did not have any effect on KSHV-induced 
EndMT (Fig. 3E and S3A-C in III). These results indicated that in our model system 
Notch, not TGF-β, pathway activation is necessary for the EndMT induction. However, 
contribution of additional signaling pathways in conjunction with Notch cannot be 
excluded for the EndMT initiation or execution, as the endothelial cell culture media used 
in these studies is rich in growth factors such as FGF and was further supplemented with 
human serum. As inhibition of the Notch pathway has been linked to increased 
lymphangiogenesis (Zheng et al., 2011), Notch pathway together with VEGF levels might 
be the responsible for distinction between angiogenesis and EndMT in the KS context.  
 
Notch signaling is overly active in the KSHV associated malignancies (KSHV induction 
of Notch signaling summarized in Figure 4): PEL cells have been shown to be dependent 
on activated Notch signaling (Lan et al., 2009), whereas Notch receptors (Notch1-4) and 
targets have been reported to be upregulated in the KS tumors (Curry et al., 2007, Curry et 
al., 2005). In LECs, it has been further shown that KSHV vFLIP and vGPCR can activate 
Notch signaling by inducing the expression of the pathway ligands Jag1 and Dll4 through 
NF-κB and ERK signaling, respectively (Emuss et al., 2009). In our system, lentiviral 
expression of either vFLIP or vGPCR in LEC led to a mesenchymal phenotype 
reminiscent of the EndMT caused by KSHV in a Notch dependent manner (Fig. 4A-D in 
III). Silencing of vFLIP or vGPCR by siRNA from the K-LEC spheroids again led to 
decreased mesenchymal sprouting (Fig. 4F-G in III). To study whether the Notch pathway 
was upstream of the known EndMT effector PDGFR-β that was upregulated by the KSHV 
infection, we analyzed its expression levels after Notch inhibition, and it was found to be 
downregulated (Fig. 3F and S3E in III). Furthermore, its silencing led to inhibited EndMT 
without affecting the Notch downstream targets  (Fig. 6D-E in III), thus suggesting that it 
indeed functions downstream of Notch. These findings suggest that it is indeed the viral 
genes that are driving the EndMT process through Notch (summarized in figure 7) and 
leading to the activation of the EndMT executor PDGFR-β.  
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Figure$7.$Notch$functions$in$KS/PEL$pathogenesis. 
KSHV proteins vGPCR, vFLIP, RTA, and v-cyclin (v-cyc) activate Notch signaling. This 
leads to increased survival and proliferation of the tumor cells (A), and, at least in some 
contexts, this is due to inhibited differentiation. In addition, Notch activation leads to 
EndMT in infected LECs (B) and inhibits angiogenesis (C). Furthermore, Notch activation 
increases KSHV lytic replication (D) (modified from (Cheng et al., 2012)). 
 
 
2.5$Increased$MMP$activity$by$KSHV$in$the$tumors$enables$invasion$and$$
spread$of$the$infected$cells$
To further analyze the effect of the KSHV expression in 3D LECs, we did a global gene 
expression analysis of the 3D cultured K-LECs and the parental non-infected LECs. The 
microarray analysis showed, that invasion related genes such as SPP1, ETS2, CXCR4, and 
PDGFRA were upregulated in K-LEC spheroids (Fig. 5A-B in III). Furthermore, the K-
LEC cells invaded into 3D collagen ten-fold more effectively than the control LECs (Fig. 
5D in III). These results suggested that the EndMT process in 3D increased the invasive 
properties of the K-LECs, and this might be important for the spread of the infected cells, 
thus allowing further expansion of the infection and the tumor progression. Indeed, it has 
been later shown that KSHV can regulate several analogical invasion/motility related 
molecules, including CXCR7 and ETS-1 (Gutierrez et al., 2013, Raggo et al., 2005, 
Totonchy et al., 2014). As MMPs are key enzymes in cancer invasion (Egeblad and Werb, 
2002), and MMP-1, -2, and -9 had been shown to be upregulated in the KSHV infected 
HUVECs (Qian et al., 2007), we deciphered their role in the EndMT related invasion by 
using specific inhibitors. Global MMP inhibitors, GM6001 and TIMP2, resulted in a 
  
!
RESULTS(AND(DISCUSSION(
!
! !
64 
decrease of the K-LEC spheroid sprouting, whereas TIMP1, an inhibitor of the secreted 
MMPs, did not (Fig. 5C in III). This implied that one of the three membrane-type (MT) 
MMPs would be causing the increased invasiveness. We could detect that KS tumors co-
expressed LANA and MT1-MMP in the tumor mass, as well as in the single cells invading 
into the surrounding stroma (Fig. 5E in III). K-LEC spheroids overexpressed MT1-MMP 
when compared to the LEC control, and siRNA silencing of MT1-MMP in the spheroid 
system led to decreased sprouting and reduced expression of PDGFRB and TAGLN (Fig. 
5F and 6A in III). MT1-MMP silencing did not significantly affect the Notch targets, 
whereas Notch inhibition led to decreased MT1-MMP expression (Fig. 6B-C in III), 
suggesting that MT1-MMP is acting downstream of Notch. In conclusion, our findings 
revealed the K-LEC invasion in 3D matrix requires initiation of EndMT by activated 
Notch signaling, followed by activation of EndMT effectors such as PDGFR-β, and 
invasion related enzymes including MT1-MMP (summarized in Figure 8).  Later, other 
studies have additionally shown that KSHV can indeed promote EndMT through Notch 
and transcription factors Slug and ZEB1 activation (Gasperini et al., 2012). 
 
 
 
 
Figure$8.$KSHV$induced$EndMT.$
KSHV vFLIP and vGPCR expression in LECs activates Notch signaling, which further 
leads to EndMT via MT1-MMP and PDGFR-β upregulation. In addition, EndMT in K-
LECs leads to upregulation of invasion related genes and increased viral reactivation, thus 
potentially facilitating the viral spread. A K-LEC spheroid stained with antibodies against 
fibronectin (green) and podoplanin (red) is shown. Nuclei were counterstained with 
Hoechst (blue). 
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3.$MELANOMA$METASTASIS$IS$AUGMENTED$BY$LEC$–$MELANOMA$CELL$
INTERACTION$(IV)$
$
3.1$3D$LEC3melanoma$co3culture$system!
Tumor microenvironment has become increasingly recognized to be an important 
regulator of tumor progression (Quail and Joyce, 2013). In melanoma, the presence of 
lymph node metastasis is considered as one of the main prognostic factors (Balch et al., 
2009), but the removal of the metastatic lymph nodes does not lead to survival benefit 
(Morton et al., 2006). This suggests that the drivers of the tumor progression occur before 
the melanoma cells have reached the lymph nodes, or that the contact of the tumor cells 
with the stromal cells within the lymph nodes leads to further changes in cancer 
progression that are not abolished by removing the lymph nodes. As the primary 
melanomas and lymph node metastases are abundant in lymphatic vessels, and the amount 
of lymphatic vessels and lymphatic vessel invasion in the primary tumors and lymph 
nodes negatively correlate with the prognosis (Dadras et al., 2005, Dadras et al., 2003), we 
hypothesized that LEC-melanoma cell interaction could lead to changes in the melanoma 
progression. This could occur through LEC induced changes in melanoma, melanoma 
induced changes in LECs, or both. To this end, we developed a method to study the 
melanoma interaction with primary LECs in a cross-linked 3D matrix. The preformed 
LEC spheroids were embedded into fibrin matrix together with GFP expressing 
melanomas as single cells (Fig. 1A in IV). In this assay, melanoma cell lines with high or 
low metastatic capacity reacted differentially. Bowes melanoma cells isolated from the 
superficially spreading melanoma increased the LEC sprouting (Fig. 1B in IV), which was 
likewise evident when the LECs were stimulated with their growth factor, VEGF-C (data 
not shown). Thus, the melanoma cells with low initial metastatic capacity increased the 
lymphangiogenic potential of the LECs. The melanoma cells from a metastatic skin lesion 
of nodular melanoma (WM852), on the other hand, inhibited the spontaneous or VEGF-C 
induced LEC sprouting, suggesting that the lymphangiogenesis is no longer needed at the 
metastatic phase of the melanoma (Fig. 1B in IV). Importantly, both of the cell lines were 
able to make space for themselves in the LEC spheroid body by downregulating 
endothelial cell markers such as endothelial adhesion molecule PECAM on LECs (Fig. 1C 
in IV). The capability of the melanoma cells to invade into the LEC spheroids seemed to 
be independent of the intrinsic metastatic properties of the cells. The seemingly different 
effects of the melanoma cells on the spheroids could reflect the different origins of these 
cell lines. The cell line from the early stage melanoma could still need the increased 
lymphangiogenesis to maximize its contact with the lymphatic vasculature and thereby 
facilitate its spread, whereas the already metastatic cell line only needs the invasive 
capacities. 
 
3.2$Melanoma$interaction$leads$to$loss$of$LEC$cell3cell$contact$and$$
identity$markers!
As both of the melanoma cell lines were able to invade into the LEC spheroid, the 
lymphatic invasion capacity seemed to be a general feature in melanoma. To study what 
are the processes needed for this invasion, we first assessed if the LEC-melanoma 
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interaction would alter the LECs to allow the melanoma invasion. The EC adherent 
junction molecule, VE-cadherin, was downregulated in LECs in contact with the 
melanoma cells both in 3D and 2D (Fig. 2A-B in IV). This suggests that the melanoma 
cells reduced integrity in the LEC spheroids/monolayer. The phenotype was dependent on 
cell-cell contacts, as the conditioned media from LEC or LEC-melanoma co-culture did 
not lead to altered VE-cadherin expression (Fig. S2 in IV). As the melanoma cells express 
a plethora of proteases (Moro et al., 2014), it was not surprising that the cell surface 
markers of LECs were altered in the presence of melanoma. In fact, it has already earlier 
been shown that cancer cells are able to downregulate endothelial markers, if the cancer 
cell spheroids are cultivated on top of a monolayer of endothelial cells (Kerjaschki et al., 
2011).  However, in addition to VE-cadherin, we could detect that Prox-1, the master 
regulator of the lymphatic endothelial cell fate, was downregulated in the LECs that were 
in contact with the melanoma cells (Fig. 2C in IV). This suggests that the melanoma cells 
are able to alter the cell fate of the LECs in a manner that could contribute to the cancer 
cell invasion.  
 
3.3$LEC$interaction$gives$rise$to$invasive$properties$in$melanoma$cells$
To decipher whether the LEC-melanoma interaction in the co-culture would give rise to 
changes in the invasive properties, the cell migration and adhesive capabilities of the cells 
were studied. The 2D cell migration was studied by using a modified wound healing 
assay, where melanoma cells and LECs were seeded onto the opposite sides of the wound. 
In the Bowes-LEC assay, this resulted in accelerated wound closure compared to the 
wound healing assays containing only either one of the cell types on both sides (Fig. S1C). 
On the contrary, WM852 wound closure was not affected by the presence of the LECs 
(data not shown). As it seemed that the faster wound closure of the Bowes-LEC assay was 
due to increased LEC migration, and WM852-LEC did not show any phenotype, it is well 
probable that this is due to the increased lymphangiogenic potential of the Bowes co-
cultured LECs seen in 3D rather than increased cancer cell migration. The adhesion of the 
melanoma cells or LECs onto a LEC layer before and after co-culture were studied by 
seeding single-cultured LECs or melanoma cells, or co-cultured cells on top of a confluent 
LEC layer as depicted in Fig. 3A in IV. The single-cultured LECs formed small colonies 
on top of the LEC layer and showed signs of apoptosis, whereas most of the single-
cultured melanoma cells that adhered disrupted the bottom LEC layer, attached to the 
bottom of the plate, and displayed flattened morphology. Strikingly, the LEC co-cultured 
melanoma cells rather attached to each other and formed large sphere like structures that 
were partially surrounded by the LECs, while the cell attachment to the plate was 
abolished (Fig. 3B in IV). The phenotype was more pronounced in the metastatic WM852 
cell line, which suggests that the co-culture of melanoma with LEC had changed their 
adhesive properties to each other especially when the tumor cell background was 
aggressive. Surprisingly, seeding of the co-cultured melanoma cells additionally led to 
downregulation of VE-cadherin, PECAM, and Prox-1 in the bottom LEC layer (Fig. 3C in 
IV), suggesting that changes in the LEC fate and identity might be contributing to the 
increased adhesion of the tumor cells.  
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To specifically assess the invasive capabilities of the co-cultured melanoma cells, we 
decided to use the more aggressive WM852 cell line showing more pronounced phenotype 
in the adhesion assay, and separated them from LECs after the co-culture by using 
magnetic nanoparticles (see workflow, Fig. 4A in IV). After the separation, the LEC co-
cultured (LEC primed) melanoma cells were subjected to adhesion assay as well as fibrin 
invasion assay. The adhesion assay revealed that the melanoma cells had gained 
capabilities during the co-culture, which allowed them to adhere together, attract cells 
from the underlying LEC monolayer, as well as downregulate the endothelial markers in 
the LEC monolayer (Fig. 4B in IV).  Furthermore, after embedding the single cells into 
fibrin, the single-cultured WM852 remained as round single cells, whereas the LEC 
primed WM852 cells started exhibiting elongated morphology already at 24 hours. While 
the WM852 cells cultured alone started forming small, round cell clusters over several 
days in fibrin, the LEC primed WM852 cells retained the elongated morphology, formed 
structures where cells lined up after each other, and showed increased invasive potential 
(Fig. 4C-D in IV). Taken together, these findings suggest that the adhesive and invasive 
capabilities of the melanoma cells were enhanced by the LEC co-culture, highlighting the 
impact of tumor-stroma interactions in gaining tumor progression traits.  
 
To decipher the molecular mechanisms behind the increased invasive potential of the co-
cultured melanoma cells, we analyzed some of the genes known to be involved in the 
melanoma invasion and metastasis. qRT-PCR analysis of the LEC primed WM852 cells 
revealed that the expression levels of CXCR4 and MT1-MMP were upregulated when 
normalized to single-cultured WM852 cells (Fig. 5A and S4A in IV). We were able to 
show that LEC conditioned medium was sufficient to upregulate CXCR4 both at mRNA 
and protein level in the WM852 cells (Fig. 5B-C in IV), suggesting that a secreted factor 
would explain this difference. Indeed, CXCR4 ligand CXCL12 was found to be 
upregulated in the WM852 primed LECs, and inhibition of CXCR4 ligand binding 
partially reverted the LEC co-culture mediated adhesion properties of the melanoma cells 
(Fig. 5D-E in IV). Fittingly, it has been earlier shown that LECs secreting the CXCL12 in 
metastatic sites recruit CXCR4+ melanoma cells, thus augmenting the melanoma 
metastasis in vivo (Kim et al., 2010). MT1-MMP expression was not altered in the 
WM852 cells treated with the LEC conditioned media, implying that the physical co-
culture gives rise to additional changes in the expression of invasion related genes 
possibly reflecting the different outcome of conditioned media and contact mediated 
changes for the invasion related phenotypes.  
 
When we analyzed the global gene expression of the LEC primed WM852 by RNA 
sequencing, we observed that a large portion of genes was differentially expressed from 
the WM852 cells cultured alone (Fig. 6A in IV). These genes included members of the 
Notch pathway (Fig. 6B in IV), which is known to induce changes in melanoma 
progression through activation of cell proliferation pathways and promoting adhesive and 
invasive properties, as well as to increase cell plasticity and metastasis (Balint et al., 2005, 
Liu et al., 2006, Bedogni et al., 2008, Asnaghi et al., 2012, Howard et al., 2013, Hardy et 
al., 2010, Topczewska et al., 2006). The qRT-PCR validation showed that LECs induce 
Notch pathway activation in melanoma through NOTCH3 receptor and target genes HES1, 
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HEY1, and HEY2 (Fig. 6C in IV). Moreover, inhibition of the Notch pathway by DAPT 
led to reversion of the co-culture mediated adhesion phenotype (Fig. 6E in IV). As a less 
pronounced effect was observed with the inhibitor of CXCR4 ligand binding, it is 
tempting to speculate that the Notch pathway could elicit part of its functions in melanoma 
through CXCR4-CXCL12 axis, similar to multiple myeloma (Mirandola et al., 2013). The 
function of Notch in melanoma development/progression is summarized in Figure 9. 
 
$
$
Figure$9.$Notch$regulation$in$melanoma.!
Notch1 or Notch4 activation has been shown to lead to activation of Akt, Nodal, and β-
catenin in melanoma, which increases melanoma cell survival and growth, vascular 
mimicry, and metastasis. We show that Notch3 in melanoma can be upregulated by the 
LEC contact, possibly through the elevated Dll4/Jag1 ligand expression on LEC. 
Melanoma-LEC contact leads to activation of adhesion, invasion, and metastasis. 
$
3.4$LEC3melanoma$interaction$leads$to$a$more$metastatic$phenotype$in#vivo$
To study the tumorigenic and metastatic capacity of melanoma cells after LEC priming in 
vivo, we injected the GFP-luciferase expressing 3D single-cultured or 3D LEC primed 
melanoma cells subcutaneously into immunocompromized Scid mice (see workflow in 
Fig. 7A in IV). The primary tumor growth rates did not change upon LEC priming, and 
the size of the WM852 tumors at the time of collection/sacrifice were similar with or 
without LEC priming, whereas the 3D LEC primed Bowes tumors were slightly larger at 
the end point (Fig. S6B-C in IV). IHC analysis of the tumors revealed that 3D LEC 
priming facilitated the stromal cell recruitment to the primary tumors, as the 3D LEC 
priming led to increased recruitment of α-SMA and fibronectin positive fibroblasts to the 
WM852 and Bowes tumors (Fig. 7C in IV).  As these markers represent activated 
fibroblasts, these cells could represent the cancer associated fibroblasts (CAFs), known 
mediators of tumor progression (Augsten, 2014). Thus, in addition to the direct LEC 
mediated effects on melanoma cells affecting the tumor cell adhesion and invasion, the 
LEC priming led to indirect effects on the tumor progression through changes in the tumor 
microenvironment.  
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Furthermore, when the metastases were analyzed by postmortem luciferase imaging, the 
LEC priming was found to significantly increase distant organ metastasis of the LEC 
primed WM852 tumors, whereas the LEC primed or non-primed Bowes cell tumors 
showed no distant organ metastasis (Fig. 7F-G and S6E in IV). These results suggest that 
LEC priming of the melanoma cells leads to alterations in the tumor stroma and increased 
metastatic capacity of the aggressive and plastic tumor cells in vivo. In mice with the 
Bowes cell tumors, distant organ metastasis was not initiated by the LEC priming. Thus, it 
is possible that the stromal cells can only unleash the already existing metastatic capacity 
of the tumor cells. Similarly, it has been shown that breast cancer cells can condition 
lymphatics in the pre-metastatic sites to generate a pre-metastatic niche and promote 
metastasis (Lee et al., 2014a, Lee et al., 2014b). In summary, the lymphatics - tumor cell 
interactions might be a general mechanism contributing to the metastasis cascade in 
collaboration with the acquired mutations of the tumor cells. 
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CONCLUSIONS$AND$FUTURE$PERSPECTIVES$
This thesis has implicated that tumor cell plasticity and cellular reprogramming can 
contribute to several steps in tumor progression. Tumor initiation can be triggered if the 
differentiation of the pre-tumorigenic cell lineage is hindered while the proliferation 
pathways are active. Moreover, false timing of morphogenetic processes such as EMT and 
EndMT can induce increased tumor invasion as well as give rise to tumor 
microenvironmental cells like CAFs. In addition, the metastasis cascade can be activated 
by tumor-stroma interactions, which reveal the plastic and aggressive nature of the tumor 
cells. The Notch pathway activation can participate in all these processes and regulate the 
malignant cascade by affecting the tumor cell plasticity. This further implies that certain 
signaling pathways can regulate multiple steps of tumorigenesis. 
 
In future, it is critical to reveal what the key mechanisms involved in regulating tumor cell 
plasticity are, so that the spread of the cancers and the resulting morbidity and mortality 
could be diminished. Additionally, it is important to understand how these mechanisms 
are regulated, and how the tumor-stroma interactions affect the tumorigenesis to further 
understand the full complexity of the malignant progression. As this study revealed that 
the Notch pathway can be induced by both virus-mediated mechanisms as well as through 
tumor-stroma interaction, it further corroborates the idea that at least KSHV and possibly 
other human tumor viruses cause cancers as side effects of their life cycle regulation by 
affecting pathways needed in both processes. Moreover, these results and reports of others 
show how viruses have evolved to deregulate the signaling pathways important for their 
spread by several, partially overlapping and complementary mechanisms. Hence, the 
tumor viruses continue to be extremely helpful in understanding the tumorigenesis process 
in general. They contain a restricted set of genes, which have an essential function for the 
viral life cycle and spread, and thus possibly for the malignant progression as well. 
Accordingly, by studying which pathways they regulate in a redundant fashion might 
reveal the important pathways critical for driving the tumor progression out of the wide 
range of changes in the tumor cells. 
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